Form 10-Q - Quarterly report [Sections 13 or 15(d)]

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2024

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from

Commission File No. 333-191725

REGEN BIOPHARMA, INC.

(Exact name of small business issuer as specified in its charter)

Nevada	45-5192997
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)

4700 Spring Street, St 304, La Mesa, California 91942

(Address of Principal Executive Offices)

619 722-5505

(Issuer’s telephone number)

None

(Former name, address and fiscal year, if changed since last report)

Check whether the issuer (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the preceding 12 months (or for such shorter period that the issuer was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes ☒ No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes ☐ No ☒

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer,” “non-accelerated filer,” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

☐ Large accelerated filer	☐ Accelerated filer
☒ Non-accelerated filer	☒ Smaller reporting company
	☐ Emerging Growth Company

APPLICABLE ONLY TO CORPORATE ISSUERS:

As of July 17, 2024 Regen Biopharma, Inc. had 4,508,320 common shares outstanding.

As of July 17, 2024 Regen Biopharma, Inc. had 10,123,771 shares of Series A Preferred Stock outstanding.

As of July 17, 2024 Regen Biopharma, Inc. had 34 shares of Series AA Preferred Stock outstanding.

As of July 17, 2024 Regen Biopharma, Inc. had 29,338 shares of Series M Preferred Stock outstanding.

As of July 17, 2024 Regen Biopharma, Inc. had 15,007 shares of Series NC Preferred Stock outstanding.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act):

Yes ☐ No ☒

PART I - FINANCIAL INFORMATION

Item 1. - Financial Statements


REGEN BIOPHARMA , INC.
CONDENSED CONSOLIDATED BALANCE SHEETS

		As of
		June 30, 2024			September 30, 2023
		(unaudited)
ASSETS
CURRENT ASSETS
Cash	$	61,849		$	121,037
Accounts Receivable, Related Party		67,147			0
Note Receivable, Related Party					0
Prepaid Expenses		10,921			0
Prepaid Rent		12,500			10,000
Total Current Assets		152,417			131,037
OTHER ASSETS
Investment Securities, Related Party		17,733			222,580
Total Other Assets		17,733			222,580
Total Assets	$	170,150		$	353,617

LIABILITIES AND STOCKHOLDERS' EQUITY
Current Liabilities:
Accounts payable		29,416			29,674
Notes Payable		218,230			95,710
Accrued payroll taxes		4,241			4,241
Accrued Interest		359,970			342,588
Accrued Payroll		1,256,630			1,256,630
Other Accrued Expenses		41,423			41,423
Bank Overdraft		1,000			1,000
Due to Investor		20,000			20,000
Unearned Income		1,496,811			1,591,731
Unearned Income (Related Party)		0			15,126
Derivative Liability		1,400,261			1,400,000
Convertible Notes Payable Less unamortized discount		499,880			499,880
Convertible Notes Payable, Related Parties Less unamortized discount		0			10,000
Total Current Liabilities		5,327,862			5,308,003
Long Term Liabilities:
Convertible Notes Payable, Related Parties Less unamortized discount
Notes Payable		0			149,614
Total Long Term Liabilities		0			149,614
Total Liabilities		5,327,862			5,457,617

STOCKHOLDERS' EQUITY (DEFICIT)
Common Stock ($.0001 par value) 500,000,000 shares authorized; 5,800,000,000 authorized and 4,373,078 issued and outstanding as of June, 2024 and 3,506,366 shares issued and outstanding as of September 30, 2023.		439			352
Preferred Stock, 0.0001 par value, 800,000,000 authorized as of June 30, 2024 and September 30, 2023 respectively
Series A Preferred; 739,000,000 authorized as of September 30, 2023 and June 30, 2024; 429,619 outstanding as of June 30, 2024 and 409,551 outstanding as of September 30, 2023		42			40
Series AA Preferred; $0.0001 par value 600,000 authorized and 34 and 34 outstanding as of June 30, 2024 and September 30,2023 respectively		0			0
Series M Preferred; $0.0001 par value 60,000,000 authorized and 29,338 outstanding as of September 30, 2023 and 60,000,000 authorized and 29,338 outstanding as of June 30, 2024		3			3
Series NC Preferred; $0.0001 par value 20,000 authorized and 15,007 outstanding as of September 30, 2023 and June 30, 2024		2			2
Additional Paid in capital		14,456,692			13,908,141
Contributed Capital		736,326			736,326
Retained Earnings (Deficit)		(20,351,216	)		(19,748,863	)
Total Stockholders' Equity (Deficit)		(5,157,712	)		(5,104,000	)
TOTAL LIABILITIES & STOCKHOLDERS' EQUITY (DEFICIT)	$	170,150		$	353,617

The Accompanying Notes are an Integral Part of These Financial Statements

All stock amounts have been retroactively adjusted to reflect a 1 for 1500 reverse stock split of all issued series of stock effective as of March 6, 2023

REGEN BIOPHARMA , INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(unaudited)


	Quarter Ended June 30, 2024			Quarter Ended June 30, 2023			Nine Months Ended June 30, 2024			Nine Months Ended June 30, 2023
REVENUES
Revenues	$	31,640		$	31,640		$	94,920		$	94,920
Revenues, Related Party		27,425			27,425			82,274			82,274
TOTAL REVENUES		59,065			59,065			177,194			177,194

COST AND EXPENSES
Research and Development		32,500			45,001			120,161			176,960
General and Administrative		16,492			9,262			38,298			36,660
Consulting and Professional Fees		95,539			74,957			295,839			546,437
Rent		22,500			15,000			54,715			45,000
Total Costs and Expenses		167,031			144,220			509,012			805,057
OPERATING INCOME (LOSS)	$	(107,966	)	$	(85,155	)	$	(331,819	)	$	(627,863	)

OTHER INCOME & (EXPENSES)
Interest Expense		(17,554	)		(14,063	)		(52,382	)		(43,507	)
Interest Expense attributable to Amortization of Discount		(4,339	)		0			(13,045	)
Unrealized Gain ( Loss) on sale of Investment Securities								(204,847	)
Derivative Income (Expense)		(261	)		0			(261	)		2,151,755
Gain (Loss) on Extinguishment Convertible Debt											1,150
TOTAL OTHER INCOME (EXPENSE)		(22,154	)		(14,063	)		(270,534	)		2,109,397

NET INCOME (LOSS)	$	(130,120	)	$	(99,218	)	$	(602,353	)	$	1,481,534
NET INCOME (LOSS) attributable to common shareholders		(117,108	)		(99,218	)	$	(602,353	)	$	1,303,750

BASIC AND FULLY DILUTED EARNINGS (LOSS) PER SHARE	$	(0.03	)	$	(0.03	)	$	(0.15	)	$	0.39

WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING		4,213,611			3,381,366			3,974,434			3,370,012

The Accompanying Notes are an Integral Part of These Financial Statements

All stock amounts have been retroactively adjusted to reflect a 1 for 1500 reverse stock split of all issued series of stock effective as of March 6, 2023

REGEN BIOPHARMA, INC.

CONDENSED CONSOLIDATED STATEMENT OF SHAREHOLDERS' EQUITY (DEFICIT)

(unaudited)


	Nine Months Ended June 30, 2024

			Series A Preferred				Series AA Preferred				Series NC Preferred				Common				Series M Preferred
10/13/2023			Shares		Amount		Shares		Amount		Shares		Amount		Shares		Amount		Shares		Amount		Additional Paid-in Capital		Retained Earnings			Contributed Capital			Total
Balance September 30, 2023	Balance September 30, 2023			409,551	$	40		34	$	0		15,007	$	2		3,506,366	$	352		29,338		3	$	13,908,141	$	(19,748,863	)	$	736,326	$	(5,104,000	)
Common Shares issued for Cash	10/13/2023	Common Shares issued for Cash				—				—				—		16,710		2				—		22,724		—			—		22,726
Common Shares issued for Cash	10/27/2023	Common Shares issued for Cash				—				—				—		35,785		4				—		46,088		—			—		46,091
Common Shares issued for Cash	11/10/2023	Common Shares issued for Cash				—				—				—		31,732		3				—		38,202		—			—		38,205
Common Shares issued for Cash	11/27/2023	Common Shares issued for Cash				—				—				—		33,989		3				—		32,626		—			—		32,629
Common Shares issued for Cash	12/11/2023	Common Shares issued for Cash				—				—				—		43,297		4				—		38,097		—			—		38,101
Common Shares issued for Cash	12/20/2023	Common Shares issued for Cash				—				—				—		82,686		8				—		34,535		—			—		34,543
	Net Income (Loss) Quarter Ended December 31, 2023					—				—				—		—		—				—		—		(349,760	)		—		(349,760	)
Balance December 31, 2023	Balance December 31, 2023			409,551	$	40		34	$	0		15,007		2		3,750,565		376		29,338		3		14,120,412		(20,098,623	)		736,326	$	(5,241,463	)
1/3/2024	1/3/2024					—				—				—		94,883		9				—		39,629		—			—		39,638
1/10/2024	1/10/2024					—				—				—		82,643		8				—		44,288		—			—		44,297
2/2/2024	2/2/2024					—				—				—		40,229		4				—		19,609		—			—		19,614
2/21/2024	2/21/2024					—				—				—		52,569		5				—		32,356		—			—		32,362
3/6/2023	3/6/2023					—				—				—		44,503		4				—		25,278		—			—		25,282
3/20/2024	3/20/2024					—				—				—		49,230		5				—		26,776		—			—		26,781
Net Income (Loss) Quarter Ended March 31, 2024	Net Income (Loss) Quarter Ended March 31, 2024					—				—				—		—		—				—		—		(122,473	)		—		(122,473	)
Net Income( Loss) Quarter Ended June 30, 2024	Balance March 31, 2024			409,551	$	40		34	$	0		15,007		2		4,114,622		413		29,338		3		14,308,349		(20,221,096			736,326	$	(5,175,963	)
4/3/2024	4/3/2024					—				—				—		52,763						—		25,321		—			—		25,326
5/2/2024	5/2/2024			20,068		2				—				—								—		13,042		—			—		13,044
5/29/2024	5/29/2024					—				—				—		68,185		7				—		29,993		—			—		30,000
6/7/2024	6/7/2024					—				—				—		62,207		6				—		29,994		—			—		30,000
6/20/2024	6/20/2024					—				—				—		75,301		8				—		49,992		—			—		50,000
Net Income( Loss) Quarter Ended June 30, 2024	Net Income( Loss) Quarter Ended June 30, 2024					—				—				—		—		—				—		—		(130,120	)		—		(130,120	)
Balance June 30, 2024	Balance June 30, 2024			429,619	$	42		34	$	0		15,007		2		4,373,078		439		29,338		3		14,456,692		(20,351,216	)		736,326	$	(5,157,712	)

The Accompanying Notes are an Integral Part of These Financial Statements

All stock amounts have been retroactively adjusted to reflect a 1 for 1500 reverse stock split of all issued series of stock effective as of March 6, 2023

REGEN BIOPHARMA, INC.

CONDENSED CONSOLIDATED STATEMENT OF SHAREHOLDERS' EQUITY ( DEFICIT)

(unaudited)

Nine Months Ended June 30, 2023


			Series A Preferred				Series AA Preferred				Series NC Preferred				Common				Series M Preferred
			Shares		Amount		Shares		Amount		Shares		Amount		Shares		Amount		Shares		Amount		Additional Paid-in Capital		Retained Earnings				Contributed Capital	Total
Balance September 30, 2022	Balance September 30, 2022			293,053	$	28		34	$	0		7	$	—		3,354,886		335		29,338	$	3	$	12,132,620	$	(20,905,369	)		$736,326	$(8,036,059)
Preferred Shares Issued for Nonemployee Services	10/25/2022	Preferred Shares Issued for Nonemployee Services		6,667	$	1				—				—				—				—		299,999		—			—	$300,000
Preferred Shares Issued for Debt	11/11/2022	Preferred Shares Issued for Debt		70,114	$	7				—				—				—				—		761,493		—			—	$761,500
Preferred Shares Issued for Interest	11/11/2022	Preferred Shares Issued for Interest		35,012	$	4				—				—				—				—		380,258		—			—	$380,262
Common Shares Issued For Interest	11/11/2022	Common Shares Issued For Interest				—				—				—		11,279		1				—		25,368		—			—	25,369
Preferred Shares Issued for Nonemployee Services	12/5/2022	Preferred Shares Issued for Nonemployee Services		1,112	$	0				—				—				—				—		48,372		—			—	$48,372
Net Income for the Quarter ended December 31, 2022	Net Income for the Quarter ended December 31, 2022					—				—				—				—				—		—		1,635,730			—	1,635,730
Balance December 31, 2022	Balance December 31, 2022			405,958	$	40		34	$	0		7	$	—		3,366,165		337		29,338		3	$	13,648,107	$	(19,269,640	)		$736,326	$(4,884,827)
Common Shares issued pursuant to round up provision	3/13/2023	Common Shares issued pursuant to round up provision				—				—				—				—				—		—		—			—	—
March 6,2023 reverse stock split		March 6,2023 reverse stock split				—				—				—		15,201		2				—		(2		—			—	0
Preferred Shares issued pursuant to round up provision	3/13/2023	Preferred Shares issued pursuant to round up provision				—				—				—				—				—		—		—			—	—
March 6,2023 reverse stock split		March 6,2023 reverse stock split		3,593		—				—				—				—				—		—		—			—	—
Preferred Shares issued for accrued salaries	3/17/2023	Preferred Shares issued for accrued salaries				—				—		15,000		2				—				—		10,048		—			—	10,050
Net Income (Loss) for the Quarter Ended March 31, 2023	Net Income (Loss) for the Quarter Ended March 31, 2023					—				—				—				—				—		—		(54,978	)		—	(54,978)
Balance March 31, 2023	Balance March 31, 2023			409,551	$	40		34	$	0		15,007	$	2		3,381,366		339		29,338		3	$	13,658,153	$	(19,324,617	)		$736,326	$(4,929,755)
Net Income (Loss) for the Quarter Ended June 30, 2023	Net Income (Loss) for the Quarter Ended June 30, 2023					—				—				—				—				—		—		(99,218	)		—	(99,218)
Balance June 30, 2023	Balance June 30, 2023			409,551	$	40		34	$	0		15,007	$	2		3,381,366	$	339		29,338		3	$	13,658,153	$	(19,423,836	)	$	736,326	$(5,028,973)

The Accompanying Notes are an Integral Part of These Financial Statements

All stock amounts have been retroactively adjusted to reflect a 1 for 1500 reverse stock split of all issued series of stock effective as of March 6, 2023

REGEN BIOPHARMA , INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(unaudited)


	Nine Months Ended			Nine Months Ended
	June 30, 2024			June 30, 2023
CASH FLOWS FROM OPERATING ACTIVITIES
Net Income (loss)	$	(602,353	)	$	1,481,534
Adjustments to reconcile net Income to net cash
Preferred Stock issued as compensation		2,324			348,372
Increase (Decrease) in Interest expense attributable to amortization of Discount		13,045
Increase (Decrease) in Accounts Payable		(258	)		604
(Increase) Decrease in Accounts Receivable		(67,148	)		197,725
Increase (Decrease) in accrued Expenses		17,383			43,507
(Increase) Decrease in Prepaid Expenses		(2,300	)		25,570
Increase(Decrease) in Contributed Capital		0
Increase ( Decrease) in Derivative Expense		261			(2,151,755	)
Increase ( Decrease) in Unearned Income		(110,047	)		(94,920	)
(Gain) Loss on forgiveness of Debt		0			(1,150	)
Unrealized Loss(Gain) on Investment Securities		204,847
Net Cash Provided by (Used in) Operating Activities	$	(544,246	)	$	(150,512	)


CASH FLOWS FROM FINANCING ACTIVITIES
Increase (Decrease) in Convertible Notes Payable		(10,000	)
Increase (Decrease) in Notes Payable		(40,502	)		100,000
Increase ( Decrease) in Common Stock issued for cash		535,560
Net Cash Provided by (Used in) Financing Activities		485,058			100,000

Net Increase (Decrease) in Cash	$	(59,188	)	$	(50,512	)

Cash at Beginning of Period	$	121,037		$	51,204
Cash at End of Period	$	61,849		$	692

Supplemental Disclosure of Noncash investing and financing activities:
Common shares Issued for Debt
Preferred Shares Issued for Debt	$	—		$	761,500
Cash Paid for Interest
Common shares Issued for Interest	$	—		$	25,369
Preferred Shares issued for Interest	$	—		$	380,262

The Accompanying Notes are an Integral Part of These Financial Statements

All stock amounts have been retroactively adjusted to reflect a 1 for 1500 reverse stock split of all issued series of stock effective as of March 6, 2023

REGEN BIOPHARMA, INC.

Notes to Condensed Consolidated Financial Statements

As of June 30, 2024

These Notes have been retroactively adjusted to reflect a 1 for 1500 reverse stock split of all issued series of stock effective as of March 6, 2023

NOTE 1. ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

The Company was organized April 24, 2012 under the laws of the State of Nevada

The Company intends to engage primarily in the development of regenerative medical applications which we intend to license from other entities up to the point of successful completion of Phase I and or Phase II clinical trials after which we would either attempt to sell or license those developed applications or, alternatively, advance the application further to Phase III clinical trials.

The Company is currently engaged in actively identifying small molecules that inhibit or express NR2F6 leading to immune cell activation for oncology applications and immune cell suppression for autoimmune disease.

The Company is in the early stages of development of its proposed products and therapies. The Company will be required to obtain approval from the FDA in order to market any of The Company’s products or therapies. No approval has been granted by the FDA for the marketing and sale of any of the Company’s products and therapies and no assurance may be given that any of the Company’s products or therapies will be granted such approval. The Company’s current plans include the development of regenerative medical applications up to the point of successful completion of Phase I and/ or Phase II clinical trials after which the Company would either attempt to sell or license those developed applications or, alternatively, advance the application further to Phase III clinical trials. The Company can provide no assurance that the Company will be able to sell or license any product or that, if such product is sold or licensed, such sale or license will be on terms favorable to the Company.

A. BASIS OF ACCOUNTING

The financial statements have been prepared using the basis of accounting generally accepted in the United States of America. Under this basis of accounting, revenues are recorded as earned and expenses are recorded at the time liabilities are incurred. The Company has adopted a September 30 year-end.

B. PRINCIPLES OF CONSOLIDATION

The consolidated financial statements include the accounts of KCL Therapeutics, Inc., a Nevada corporation and wholly owned subsidiary of Regen. Significant inter-company transactions have been eliminated.

The Company analyzes the conversion feature of Convertible Notes for derivative accounting consideration under ASC 815-15 “Derivatives and Hedging. ASC 815-15 requires that the conversion features are bifurcated and separately accounted for as an embedded derivative contained in the Company’s convertible debt. The embedded derivative is carried on the balance sheet at fair value. Any unrealized change in fair value, as determined at each measurement period, is recorded as a component of the income statement and the associated carrying amount on the balance sheet is adjusted by the change. The Company values the embedded derivative using the Black-Scholes pricing model.

The Black Scholes pricing model used to determine the Derivative Liability on convertible notes issued by the Company in which an embedded derivative is recognized as of June 30, 2024 utilized the following inputs:

Schedule of Derivative liability
Schedule of Derivative liability
Risk Free Interest Rate	5.39	%
Expected Term	(3.53) – (4.16) Yrs
Expected Volatility	1128.35	%
Expected Dividends

H. INCOME TAXES

The Company accounts for income taxes using the liability method prescribed by ASC 740, “Income Taxes.” Under this method, deferred tax assets and liabilities are determined based on the difference between the financial reporting and tax bases of assets and liabilities using enacted tax rates that will be in effect in the year in which the differences are expected to reverse. The Company records a valuation allowance to offset deferred tax assets if based on the weight of available evidence, it is more-likely-than-not that some portion, or all, of the deferred tax assets will not be realized. The effect on deferred taxes of a change in tax rates is recognized as income or loss in the period that includes the enactment date.

The Company applied the provisions of ASC 740-10-50, “Accounting For Uncertainty In Income Taxes”, which provides clarification related to the process associated with accounting for uncertain tax positions recognized in our financial statements. Audit periods remain open for review until the statute of limitations has passed. The completion of review or the expiration of the statute of limitations for a given audit period could result in an adjustment to the Company’s liability for income taxes. Any such adjustment could be material to the Company’s results of operations for any given quarterly or annual period based, in part, upon the results of operations for the given period. As of June 30, 2024 the Company had no uncertain tax positions, and will continue to evaluate for uncertain positions in the future.

The Company generated a deferred tax credit through net operating loss carry forward. However, a valuation allowance of 100% has been established.

Interest and penalties on tax deficiencies recognized in accordance with ACS accounting standards are classified as income taxes in accordance with ASC Topic 740-10-50-19.

I. BASIC EARNINGS (LOSS) PER SHARE

The Financial Accounting Standards Board (FASB) issued Accounting Standards Codification (ASC) 260, “Earnings Per Share”, which specifies the computation, presentation and disclosure requirements for earnings (loss) per share for entities with publicly held common stock. ASC 260 requires the presentation of basic earnings (loss) per share and diluted earnings (loss) per share. The Company has adopted the provisions of ASC 260 effective from inception.

Basic net loss per share amounts is computed by dividing the net income by the weighted average number of common shares outstanding.

J. ADVERTISING

Costs associated with advertising are charged to expense as incurred. Advertising expenses were $0 for the quarters ended June 30, 2023 and June 30, 2024.

K. NOTES RECEIVABLE

Notes receivable are stated at cost, less impairment, if any.

L. REVENUE RECOGNITION

Sales of products and related costs of products sold are recognized when: (i) persuasive evidence of an arrangement exists; (ii) delivery has occurred; (iii) the price is fixed or determinable; and (iv) collectability is reasonably assured. These terms are typically met upon the prepayment or invoicing and shipment of products.

The Company determines the amount and timing of royalty revenue based on its contractual agreements with intellectual property licensees. The Company recognizes royalty revenue when earned under the terms of the agreements and when the Company considers realization of payment to be probable. Where royalties are based on a percentage of licensee sales of royalty-bearing products, the Company recognizes royalty revenue by applying this percentage to the Company’s estimate of applicable licensee sales. The Company bases this estimate on an analysis of each licensee’s sales results. Where warranted, revenue from licensees for contractual obligations such as License Initiation Fees are recognized upon satisfaction of all conditions required to be satisfied in order for that revenue to have been earned by the Company.

M. INTEREST RECEIVABLE

Interest receivable is stated at cost, less impairment, if any.

NOTE 2. RECENT ACCOUNTING PRONOUNCEMENTS

In June 2014, the Financial Accounting Standards Board issued Accounting Standards Update No. 2014-10, which eliminated certain financial reporting requirements of companies previously identified as “Development Stage Entities” (Topic 915). The amendments in this ASU simplify accounting guidance by removing all incremental financial reporting requirements for development stage entities. The amendments also reduce data maintenance and, for those entities subject to audit, audit costs by eliminating the requirement for development stage entities to present inception-to-date information in the statements of income, cash flows, and shareholder equity. Early application of each of the amendments is permitted for any annual reporting period or interim period for which the entity’s financial statements have not yet been issued (public business entities) or made available for issuance (other entities). Upon adoption, entities will no longer present or disclose any information required by Topic 915. The Company has adopted this standard.

As of the fiscal year ending September 30, 2019 the Company has adopted Accounting Standards Update 2014-09, Revenue from Contracts with Customers (Topic 606). The guidance in this Update supersedes the revenue recognition requirements in Topic 605, Revenue Recognition, and most industry-specific guidance throughout the Industry Topics of the Codification.

The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve that core principle, an entity should apply the following steps: Step 1: Identify the contract(s) with a customer. Step 2: Identify the performance obligations in the contract. Step 3: Determine the transaction price. Step 4: Allocate the transaction price to the performance obligations in the contract. Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation.

In June 2014, FASB issued Accounting Standards Update (ASU) No. 2014-12 Compensation — Stock Compensation (Topic 718), Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period. A performance target in a share-based payment that affects vesting and that could be achieved after the requisite service period should be accounted for as a performance condition under Accounting Standards Codification (ASC) 718, Compensation — Stock Compensation. As a result, the target is not reflected in the estimation of the award’s grant date fair value. Compensation cost would be recognized over the required service period, if it is probable that the performance condition will be achieved. The guidance is effective for annual periods beginning after 15 December 2015 and interim periods within those annual periods. Early adoption is permitted. The Company has reviewed the applicable ASU and has not, at the current time, quantified the effects of this pronouncement, however it believes that there will be no material effect on the consolidated financial statements.

In August 2014, FASB issued Accounting Standards Update (ASU) No. 2014-15 Preparation of Financial Statements – Going Concern (Subtopic 205-40), Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern. Under generally accepted accounting principles (GAAP), continuation of a reporting entity as a going concern is presumed as the basis for preparing financial statements unless and until the entity’s liquidation becomes imminent. Preparation of financial statements under this presumption is commonly referred to as the going concern basis of accounting. If and when an entity’s liquidation becomes imminent, financial statements should be prepared under the liquidation basis of accounting in accordance with Subtopic 205-30, Presentation of Financial Statements—Liquidation Basis of Accounting. Even when an entity’s liquidation is not imminent, there may be conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern. In those situations, financial statements should continue to be prepared under the going concern basis of accounting, but the amendments in this Update should be followed to determine whether to disclose information about the relevant conditions and events. The amendments in this Update are effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. Early application is permitted. The Company will evaluate the going concern considerations in this ASU, however, at the current period, management does not believe that it has met the conditions which would subject these financial statements for additional disclosure.

On January 31, 2013, the FASB issued Accounting Standards Update [ASU] 2013-01, entitled Clarifying the Scope of Disclosures about Offsetting Assets and Liabilities. The guidance in ASU 2013-01 amends the requirements in the FASB Accounting Standards Codification [FASB ASC] Topic 210, entitled Balance Sheet. The ASU 2013-01 amendments to FASB ASC 210 clarify that ordinary trade receivables and receivables in general are not within the scope of ASU 2011-11, entitled Disclosure about Offsetting Assets and Liabilities, where that ASU amended the guidance in FASB ASC 210. As those disclosures now are modified with the ASU 2013-01 amendments, the FASB ASC 210 balance sheet offsetting disclosures now clearly are applicable only where reporting entities are involved with bifurcated embedded derivatives, repurchase agreements, reverse repurchase agreements, and securities borrowing and lending transactions that either are offset using the FASB ASC 210 or 815 requirements, or that are subject to enforceable master netting arrangements or similar agreements. ASU 2013-01 is effective for annual reporting periods beginning on or after January 1, 2013, and interim periods within those annual periods. The adoption of this ASU is not expected to have a material impact on our financial statements.

On February 28, 2013, the FASB issued Accounting Standards Update [ASU] 2013-04, entitled Obligations Resulting from Joint and Several Liability Arrangements for Which the Total Amount of the Obligation Is Fixed at the Reporting Date. The ASU 2013-04 amendments add to the guidance in FASB Accounting Standards Codification [FASB ASC] Topic 405, entitled Liabilities and require reporting entities to measure obligations resulting from certain joint and several liability arrangements where the total amount of the obligation is fixed as of the reporting date, as the sum of the following:

The amount the reporting entity agreed to pay on the basis of its arrangement among co-obligors.

Any additional amounts the reporting entity expects to pay on behalf of its co-obligors.

While early adoption of the amended guidance is permitted, for public companies, the guidance is required to be implemented in fiscal years, and interim periods within those years, beginning after December 15, 2013. The amendments need to be implemented retrospectively to all prior periods presented for obligations resulting from joint and several liability arrangements that exist at the beginning of the year of adoption. The adoption of ASU 2013-04 is not expected to have a material effect on the Company’s operating results or financial position.

On April 22, 2013, the FASB issued Accounting Standards Update [ASU] 2013-07, entitled Liquidation Basis of Accounting. With ASU 2013-07, the FASB amends the guidance in the FASB Accounting Standards Codification [FASB ASC] Topic 205, entitled Presentation of Financial Statements. The amendments serve to clarify when and how reporting entities should apply the liquidation basis of accounting. The guidance is applicable to all reporting entities, whether they are public or private companies or not-for-profit entities. The guidance also provides principles for the recognition of assets and liabilities and disclosures, as well as related financial statement presentation requirements. The requirements in ASU 2013-07 are effective for annual reporting periods beginning after December 15, 2013, and interim reporting periods within those annual periods. Reporting entities are required to apply the requirements in ASU 2013-07 prospectively from the day that liquidation becomes imminent. Early adoption is permitted. The adoption of ASU 2013-07 is not expected to have a material effect on the Company’s operating results or financial position.

In January 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (ASU) 2016-01, which amends the guidance in U.S. GAAP on the classification and measurement of financial instruments. Changes to the current guidance primarily affect the accounting for equity investments, financial liabilities under the fair value option, and the presentation and disclosure requirements for financial instruments. In addition, the ASU clarifies guidance related to the valuation allowance assessment when recognizing deferred tax assets resulting from unrealized losses on available-for-sale debt securities. The new standard is effective for fiscal years and interim periods beginning after December 15, 2017, and upon adoption, an entity should apply the amendments by means of a cumulative-effect adjustment to the balance sheet at the beginning of the first reporting period in which the guidance is effective. Early adoption is not permitted except for the provision to record fair value changes for financial liabilities under the fair value option resulting from instrument-specific credit risk in other comprehensive income. The Company adopted ASU 2016-01 as of the fiscal year ending September 30, 2019.

In August 2020, FASB issued ASU 2020-06, Accounting for Convertible Instruments and Contracts in an Entity; Own Equity (“ASU 2020-06”), as part of its overall simplification initiative to reduce costs and complexity of applying accounting standards while maintaining or improving the usefulness of the information provided to users of financial statements. Among other changes, the new guidance removes from GAAP separation models for convertible debt that require the convertible debt to be separated into a debt and equity component, unless the conversion feature is required to be bifurcated and accounted for as a derivative or the debt is issued at a substantial premium. As a result, after adopting the guidance, entities will no longer separately present such embedded conversion features in equity, and will instead account for the convertible debt wholly as debt. The new guidance also requires use of the “if-converted” method when calculating the dilutive impact of convertible debt on earnings per share, which is consistent with the Company’s current accounting treatment under the current guidance. The guidance is effective for financial statements issued for fiscal years beginning after December 15, 2021, and interim periods within those fiscal years, with early adoption permitted, but only at the beginning of the fiscal year. The Company has adopted ASU 2020-06 as of the Fiscal Year ending September 30, 2022.

A variety of proposed or otherwise potential accounting standards are currently under study by standard setting organizations and various regulatory agencies. Due to the tentative and preliminary nature of those proposed standards, the Company’s management has not determined whether implementation of such standards would be material to its financial statements.

NOTE 3. GOING CONCERN

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The Company generated net losses of $20,331,216 during the period from April 24, 2012 (inception) through June 30, 2024. This condition raises substantial doubt about the Company’s ability to continue as a going concern. The Company’s continuation as a going concern is dependent on its ability to meet its obligations, to obtain additional financing as may be required and ultimately to attain profitability. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

On September 12, 2023 the Company entered into a common stock purchase agreement (the “Equity Line Agreement”) with Coventry Enterprises LLC (“Coventry”) providing for an equity financing facility (the “Equity Line”). The Equity Line Agreement provides that upon the terms and subject to the conditions in the Equity Line Agreement, Coventry is committed to purchase up to Ten Million Dollars ($10,000,000) of shares of common stock, $0.0001 par value per share (the “Common Stock”), over the 36-month term of the Equity Line Agreement (the “Total Commitment”).

Under the terms of the Equity Line Agreement, Coventry will not be obligated to purchase shares of Common Stock unless and until certain conditions are met, including but not limited to a Registration Statement on Form S-1 (the “Registration Statement”) becoming effective which registers Coventry’s resale of any Common Stock purchased by Coventry under the Equity Line.

From time to time over the 36-month term of the Commitment Period ( as such term is defined in the Equity Line Agreement) the Company, in its sole discretion, may provide Coventry with a draw down notice (each, a “Draw Down Notice”), to purchase a specified number of shares of Common Stock (each, a “Draw Down Amount Requested”), subject to the limitations discussed below. The actual amount of proceeds the Company will receive pursuant to each Draw Down Notice (each, a “Draw Down Amount”) is to be determined by multiplying the Draw Down Amount Requested by the applicable purchase price. The purchase price of each share of Common Stock equals 80% of the lowest trading price of the Common Stock during the ten business days prior to the Draw Down Notice date (the “Pricing Period”).

The maximum number of shares of Common Stock requested to be purchased pursuant to any single Draw Down Notice cannot exceed the lesser of (i) 200% of the Average Daily Traded Value (as such term is defined in the Equity Line Agreement) during the ten business days immediately preceding the Drawdown Notice Date or (ii) $250,000. The Company is prohibited from delivering a Draw Down Notice if the sale of shares of Common Stock pursuant to the Draw Down Notice would cause the Company to issue and sell to Coventry or Coventry to acquire or purchase an aggregate number of shares of Common Stock that would result in Coventry beneficially owning more than 4.99% of the issued and outstanding shares of Common Stock of the Company.

The Company issued Coventry 125,000 shares of its Common Stock in connection with the Equity Line Agreement.

Coventry has agreed that:

(a)

for so long as the market price of the Company’s common stock is above $1.25 per share and

(b)

the Company is in full compliance with all agreements entered into with Coventry and

(c)

and the Company has not issued any common shares at a per share price below $1.50, Coventry will agree to a leak out provision and will not sell more than 10,000 shares of the Commitment shares without permission from the Issuer.

In connection with the Equity Line Agreement the Company also entered into a Registration Rights Agreement, dated September 12, 2023 with Coventry (the “Registration Rights Agreement”), pursuant to which the Company agreed to register for resale under the Securities Act of 1933 shares issuable in accordance with the Equity Line Agreement as well as the aforementioned 125,000 common shares issued in connection with the Equity Line Agreement in a Registration Statement to be filed with the Securities and Exchange Commission. Up to 1,126,954 Shares of Common Stock were registered for resale under the Securities Act of 1933 pursuant to the Registration Rights Agreement.

During the quarter ended December 31, 2023 the Company issued 244,199 common shares pursuant to the Equity Line Agreement for aggregate cash consideration of $212,296. During the Quarter ended March 31, 2024 the Company issued 364,057 common shares pursuant to the Equity Line Agreement for aggregate cash consideration of $187,937. During the Quarter ended June 30, 2024 the Company issued 258,456 common shares pursuant to the Equity Lune Agreement for aggregate cash consideration of $135,326.

NOTE 4. NOTES PAYABLE

(a) RELATED PARTY

Notes payable related party
	As of June 30, 2024
David Koos	$	1,708
Zander Therapeutics, Inc.	$	40,000
Total:	$	41,708

$1,708 lent to the Company by David Koos is due and payable at the demand of the holder and bears simple interest at a rate of 15% per annum.

$15,000 lent to the Company by Zander Therapeutics, Inc. is due and payable on May 3. 2025 and bears simple interest at a rate of 10% per annum.

$25,000 lent to the Company by Zander Therapeutics, Inc. is due and payable on June 5. 2025 and bears simple interest at a rate of 10% per annum.

Zander Therapeutics, Inc. and the Company are under common control.

(b) NON RELATED PARTY As of March 31, 2024

Schedule of non related party
Bostonia Partners, Inc	$	48,500
Coventry Enterprises LLC	$	140,000
Total:	$	188,500

$48,500 lent to the Company by Bostonia Partners, Inc is due and payable on March 10, 2024 and bears simple interest at a rate of 10% per annum.

Effective September 12, 2023 Coventry Enterprises purchased a 10% unsecured promissory Note (the “Note”) from the Company in the principal amount of $175,000 of which $26,250 was retained by Coventry through an Original Issue Discount.

The Note carries “Guaranteed Interest” on the principal amount at the rate of 10% per annum for the eighteen-month term of the Note for an aggregate Guaranteed Interest $26,250. The Principal Amount and the Guaranteed Interest shall be due and payable in seven equal monthly payments of $28,750 commencing on August 12, 2024 and continuing on the 12th day of each month thereafter until paid in full not later than March 12, 2025(the “Maturity Date”).

Upon an Event of Default (as such term is defined in the Note) the Note shall become convertible, in whole or in part, into shares of Common Stock at the option of the Holder at price per share equivalent to 90% of the lowest per-share trading price for the 20 Trading Days preceding a Conversion Date.

Upon the event that while this Note has been outstanding for four months, the Company consummates another financing transaction or if the Company has an effective Regulation A Offering Statement then the Investor may choose to convert any amount up to the entire balance of the note including guaranteed interest into shares at the same offering price as the aforementioned financing transaction or the Regulation A Offering. The outstanding principal balance of the Note is $140,000 as of June 30, 2024.

NOTE 5. CONVERTIBLE NOTES PAYABLE

On March 8, 2016 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $100,000 for consideration consisting of $100,000 cash. The Note pays simple interest in the amount of 8% per annum . The maturity of the Note is three years from the issue date.

The Lender shall have the right from time to time to convert all or a part of the outstanding and unpaid principal amount of this Note into fully paid and non- assessable shares of Common Stock, as such Common Stock exists on the Issue Date, or any shares of capital stock or other securities of the Company into which such Common Stock shall hereafter be changed or reclassified pursuant to the following terms and conditions:

(a) For the period beginning on the Issue Date and ending 365 days subsequent to the Issue Date (“Year 1”) a 50% discount to the lowest Trading Price (as defined below) for the Common Stock during the ten (10) Trading Day (as defined below) period ending on the latest complete Trading Day prior to the Conversion Date or $150 per share (whichever is greater).

(b) For the period beginning one day subsequent to the final day of Year One and ending 365 days subsequent to Year One (“Year 2”) a 35% discount to the lowest Trading Price (as defined below) for the Common Stock during the ten (10) Trading Day (as defined below) period ending on the latest complete Trading Day prior to the Conversion Date or $150 per share (whichever is greater).

(c) For the period beginning one day subsequent to the final day of Year 2 and ending 365 days subsequent to Year 2 (“Year 3”) a 25% discount to the lowest Trading Price (as defined below) for the Common Stock during the ten (10) Trading Day (as defined below) period ending on the latest complete Trading Day prior to the Conversion Date or $150 per share (whichever is greater).

(d) “Trading Price” means the closing bid price on the Over-the-Counter Bulletin Board, or applicable trading market (the “OTCQB”) as reported by a reliable reporting service (“Reporting Service”) designated by the Lender (i.e. Bloomberg) or, if the OTCQB is not the principal trading market for such security, the closing bid price of such security on the principal securities exchange or trading market where such security is listed or traded or, if no closing bid price of such security is available in any of the foregoing manners, the average of the closing bid prices of any market makers for such security that are listed in the “pink sheets” by the National Quotation Bureau, Inc. If the Trading Price cannot be calculated for such security on such date in the manner provided above, the Trading Price shall be the fair market value as mutually determined by the Company and the Lender. “Trading Day” shall mean any day on which the Common Stock is tradable for any period on the OTCQB, or on the principal securities exchange or other securities market on which the Common Stock is then being traded. “Trading Volume” shall mean the number of shares traded on such Trading Day as reported by such Reporting Service. The Conversion Price shall be equitably adjusted for stock splits, stock dividends, rights offerings, combinations, recapitalization, reclassifications, extraordinary distributions and similar events by the Company relating to the Lender’s securities.

The Company shall have the right, exercisable on not less than five (5) Trading Days prior written notice to the Lender, to prepay the outstanding Note in part or in full, including outstanding principal and accrued interest.

Upon closing of a Transaction Event the Lender shall receive 0 .10% ( one tenth of one percent)of the consideration actually received by the Company from an unaffiliated third party as a result of the closing of a Transaction Event.

“Transaction Event” shall mean either of:

(a) The sale by the Company of the Company’s proprietary NR2F6 intellectual property to an unaffiliated third party

(b) The granting of a license by the Company to an unaffiliated third party granting that unaffiliated third party the right to develop and/or commercialize the Company’s proprietary NR2F6 intellectual property.

As of June 30, 2024 $100,000 of the principal amount of the Note remains outstanding.

On April 6, 2016 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $50,000 for consideration consisting of $50,000 cash. The Note pays simple interest in the amount of 8% per annum . The maturity of the Note is three years from the issue date.

Upon closing of a Transaction Event the Lender shall receive 0 .10% ( one tenth of one percent) of the consideration actually received by the Company from an unaffiliated third party as a result of the closing of a Transaction Event.

“Transaction Event” shall mean either of:

(a) The sale by the Company of the Company’s proprietary NR2F6 intellectual property to an unaffiliated third party

As of June 30, 2024 $50,000 of the principal amount of the Note remains outstanding.

On October 31, 2016 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $50,000 for consideration consisting of $50,000 cash. The Note pays simple interest in the amount of 10% per annum . The maturity of the Note is two years from the issue date.

The Lender shall have the right from time to time to convert all or a part of the outstanding and unpaid principal amount of this Note into fully paid and non- assessable shares of Common Stock and/or Series A Preferred Stock, as such Stock exists on the Issue Date, or any shares of capital stock or other securities of the Company into which such Stock shall hereafter be changed or reclassified at a conversion price of $18.75 per share.

The Company shall have the right, exercisable on not less than ten (10) Trading Days prior written notice to the Lender, to prepay the outstanding Note in part or in full, including outstanding principal and accrued interest.

As of June 30, 2024 $50,000 of the principal amount of the Note remains outstanding

On May 5, 2017 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $200,000 for consideration consisting of $200,000 cash. The Note pays simple interest in the amount of 10% per annum . The maturity of the Note is May 5, 2020. The Note is convertible into the Common Shares of Regen at a price per share ( “Conversion Price”) equivalent to the lower of (a) a 75% discount to the closing price of the common stock of the Company on the trading day immediately prior to the date a conversion notice is given by the Lender to Regen or (b) $375 per common share as of the date which is the earlier of:

(i) One day subsequent to the execution of an agreement to a transaction whose completion would result in a “Change of Control” of the Company. For purposes of this Note, a Change of Control shall be defined as any transaction or series of transactions, whether by merger, sale of substantially all of the assets, or sale or transfer of more than fifty percent (50%) of the outstanding stock of the relevant entity in which the members of the Board of Directors immediately preceding the closing of the Change of Control transaction no longer constitute a majority of the Board of Directors of the surviving entity following the closing of such transaction.

ii) One day subsequent to the commencement, in compliance with applicable law, of a broad solicitation by a third party to purchase a majority percentage of the Company’s outstanding equity securities for a limited period of time contingent on shareholders of the Company tendering a fixed number of their equity securities (“Tender Offer”).

(iii) That date which is twenty four (24) months subsequent to the date of execution of this Note.

In the event that that the Company exercises its right to prepay the note, or if the Lender chooses not to convert the remaining amount of the note into Common Shares of the company, the Lender shall receive warrants equal to 10% of the Common shares it would have received had the Lender converted the remaining amount of the Note into Common shares of the Company. The warrants shall have a strike price of $75 per share.

The warrants shall be exercisable:

In the event that the Company exercises its right to Prepay the Note on or prior to the close of business on the three (3) month anniversary of the date that the Note shall have been prepaid by the Company(“Prepayment Date”)

In the event , part of the outstanding and unpaid principal amount of this Note and any Accrued Interest remains outstanding on the Maturity Date of the Note, or prior to the close of business on the three (3) month anniversary of the Maturity Date of the Note

As of June 30, 2024 $200,000 of the principal amount of the Note remains outstanding.

The Company analyzed the conversion feature of the Note for derivative accounting consideration under ASC 815-15 “Derivatives and Hedging” and determined that the embedded conversion feature should be classified as a liability due to their being no explicit limit to the number of shares to be delivered upon settlement of the above conversion features. ASC 815-15 requires that the conversion features are bifurcated and separately accounted for as an embedded derivative contained in the Company’s convertible debt. The embedded derivative is carried on the balance sheet at fair value. Any unrealized change in fair value, as determined at each measurement period, is recorded as a component of the income statement and the associated carrying amount on the balance sheet is adjusted by the change.

The Company values the embedded derivative using the Black-Scholes pricing model and a derivative liability of $800,149 was recognized by the Company as of June 30, 2024.

On December 20, 2017 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $100,000 for consideration consisting of $100,000 cash. The Note pays simple interest in the amount of 10% per annum. The maturity of the Note is December 20, 2020. The Note may be converted into the Common Shares of Regen at a price per share ( “Conversion Price”) equivalent to the lower of (a) a 75% discount to the closing price of the common stock of the Company on the trading day immediately prior to the date a conversion notice is given by the Lender to Regen or (b) $37.50 per common share as of the date which is the earlier of:

(i) One day subsequent to the execution of an agreement to a transaction whose completion would result in a “Change of Control” of the Company or KCL Therapeutics. For purposes of this Note, a Change of Control shall be defined as any transaction or series of transactions, whether by merger, sale of substantially all of the assets, or sale or transfer of more than fifty percent (50%) of the outstanding stock of the relevant entity in which the members of the Board of Directors immediately preceding the closing of the Change of Control transaction no longer constitute a majority of the Board of Directors of the surviving entity following the closing of such transaction.

(ii) One day subsequent to the commencement, in compliance with applicable law, of a broad solicitation by a third party to purchase a majority percentage of the Company’s outstanding equity securities for a limited period of time contingent on shareholders of the Company tendering a fixed number of their equity securities (“Tender Offer”).

(iv) One day subsequent to a “Transaction Event”)

Transaction Event” shall mean either of:

(a) The sale by the Company or by KCL Therapeutics , Inc. of the Company’s proprietary NR2F6 intellectual property to an unaffiliated third party

(b) The granting of a license by the Company or by KCL Therapeutics , Inc to an unaffiliated third party granting that unaffiliated third party the right to develop and/or commercialize the Company’s proprietary NR2F6 intellectual property

(v) That date which is twenty four (24) months subsequent to the date of execution of this Note.

The warrants shall be exercisable:

As of June 30, 2024 $100,000 of the principal amount of the Note remains outstanding.

The Company values the embedded derivative using the Black-Scholes pricing model and a derivative liability of $400,075 was recognized by the Company as of June 30, 2024.

On October 3, 2017 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $50,000 for consideration consisting of $50,000 cash. The Note pays simple interest in the amount of 10% per annum. The maturity of the Note is October 3, 2020. The Note may be converted into the Common Shares of Regen at a price per share ( “Conversion Price”) equivalent to the lower of (a) a 75% discount to the closing price of the common stock of the Company on the trading day immediately prior to the date a conversion notice is given by the Lender to Regen or (b) $37.5 per common share as of the date which is the earlier of:

(iv) One day subsequent to a “Transaction Event”)

Transaction Event” shall mean either of:

(a) The sale by the Company or by KCL Therapeutics , Inc. of the Company’s proprietary NR2F6 intellectual property to an unaffiliated third party

(v) That date which is twenty four (24) months subsequent to the date of execution of this Note.

The warrants shall be exercisable:

As of June 30, 2024, $50,000 of the principal amount of the Note remains outstanding.

The Company values the embedded derivative using the Black-Scholes pricing model and a derivative liability of $200,037 was recognized by the Company as of June 30, 2024.

NOTE 6. RELATED PARTY TRANSACTIONS

On June 23, 2015 the Company entered into an agreement (“Agreement”) with Zander Therapeutics, Inc. ( “Zander”) whereby The Company granted to Zander an exclusive worldwide right and license for the development and commercialization of certain intellectual property controlled by The Company (” License IP”) for non-human veterinary therapeutic use for a term of fifteen years. Zander is under common control with the Company.

Pursuant to the Agreement, Zander shall pay to The Company one-time, non-refundable, upfront payment of one hundred thousand US dollars ($100,000) as a license initiation fee which must be paid within 90 days of June 23, 2015 and an annual non-refundable payment of one hundred thousand US dollars ($100,000) on July 15th, 2016 and each subsequent anniversary of the effective date of the Agreement.

The abovementioned payments may be made, at Zander’s discretion, in cash or newly issued common stock of Zander.

Pursuant to the Agreement, Zander shall pay to The Company royalties equal to four percent (4%) of the Net Sales , as such term is defined in the Agreement, of any Licensed Products, as such term is defined in the Agreement, in a Quarter.

Pursuant to the Agreement, Zander will pay The Company ten percent (10%) of all consideration (in the case of in-kind consideration, at fair market value as monetary consideration) received by Zander from sublicensees ( excluding royalties from sublicensees based on Net Sales of any Licensed Products for which The Company receives payment pursuant to the terms and conditions of the Agreement).

Zander is obligated pay to The Company minimum annual royalties of ten thousand US dollars ($10,000) payable per year on each anniversary of the Effective Date of this Agreement, commencing on the second anniversary of June 23, 2015. This minimum annual royalty is only payable to the extent that royalty payments made during the preceding 12-month period do not exceed ten thousand US dollars ($10,000).

The Agreement may be terminated by The Company:

If Zander has not sold any Licensed Product by ten years of the effective date of the Agreement or Zander has not sold any Licensed Product for any twelve (12) month period after Zander’s first commercial sale of a Licensed Product.

The Agreement may be terminated by Zander with regard to any of the License IP if by five years from the date of execution of the Agreement a patent has not been granted by the United States patent and Trademark Office to The Company with regard to that License IP.

The Agreement may be terminated by Zander with regard to any of the License IP if a patent that has been granted by the United States patent and Trademark Office to The Company with regard to that License IP is terminated.

The Agreement may be terminated by either party in the event of a material breach by the other party.

On December 17, 2018 Regen Biopharma, Inc.(“Licensor”) , KCL Therapeutics, Inc. (“Assignee”) and Zander Therapeutics, Inc. (“Licensee”) entered into a LICENSE ASSIGNMENT AND CONSENT AGREEMENT whereby, with regards to certain intellectual property which was assigned by Regen Biopharma, Inc.(“Assigned Properties”) to its wholly owned subsidiary KCL Therapeutics, Inc., Licensor hereby transfers and assigns to Assignee all rights, duties, and obligations of Licensor under the Agreement with respect to the Assigned Properties , and Assignee agrees to assume such duties and obligations thereunder and be bound to the terms of the Agreement with respect thereto.

On December 16, 2019 Zander Therapeutics, Inc. (“Zander”), KCL Therapeutics, Inc. (“KCL”) and Regen Biopharma, Inc. (“Regen”) entered into an agreement (“Agreement”) whereby:

1) Zander shall return for cancellation 194,285,714 shares of the Series A Preferred stock of Regen (“Conversion Shares”) acquired by Zander through conversion of $340,000 of principal indebtedness of a $350,000 convertible note payable issued by Regen to Zander. Subsequent to this event the principal amount due to Zander by Regen pursuant to the Convertible Note shall be $350,000 which shall be applied pursuant to the Agreement.

2) A $35,000 one time charge due to Zander by Regen (“One Time Charge”) shall be applied pursuant to the Agreement.

3) $75,900 of principal indebtedness due to Regen by Zander and $4,328 of accrued but unpaid interest due by Regen to Zander shall be applied pursuant to the Agreement.

No actions were taken by any of the parties to enforce the terms of the Agreement.

On April 15, 2021 the Agreement was amended as follows so that the material terms and conditions shall be:

a) Zander shall not return the Conversion shares for cancellation and the principal indebtedness of the aforementioned convertible note shall not reflect such return

b) As of December 16, 2019 all principal and accrued interest payable by Regen to Zander on that date resulting from Promissory Notes issued by Regen to Zander shall be credited towards amounts due by Zander pursuant to that agreement, as amended, entered into by and between Zander and Regen on June 23, 2015 (“License Agreement”) whereby Regen granted to Zander an exclusive worldwide right and license for the development and commercialization of certain intellectual property controlled by Regen for non-human veterinary therapeutic use for a term of fifteen years and that License Assignment And Consent agreement entered into by and between Regen, KCL and Zander on December 17, 2018 whereby Regen transferred and assigned to KCL all rights, duties, and obligations of Regen under the License Agreement and KCL agreed to assume such duties and obligations thereunder and be bound to the terms of the License Agreement with respect thereto.

Zander and Regen are under common control.

On September 30, 2018 Regen Biopharma, Inc. (“Regen”) issued a convertible promissory note in the principal amount of $350,000 (“Note”) to Zander Therapeutics, Inc. (“Zander”). Consideration for the Note consisted of $350,000. A onetime interest charge of 10% of the principal amount shall be applied to the principal amount of the Note. The Note is due and payable 24 months from the effective date.

Zander has the right, at any time after the September 30, 2018, at its election, to convert all or part of the outstanding and unpaid Principal Sum and accrued interest (and any other fees) into shares of fully paid and non-assessable shares of Series A Preferred stock of Regen as per this conversion formula: Number of shares receivable upon conversion equals the dollar conversion amount divided by the Conversion Price. The Conversion Price is the greater of $0.0001 or 60% of the lowest trade price in the 25 trading days previous to the conversion. Zander, at any time prior to selling all of the shares from a conversion, may, for any reason, rescind any portion, in whole or in part, of that particular conversion attributable to the unsold shares and have the rescinded conversion amount returned to the Principal Sum with the rescinded conversion shares returned to Regen.

As of June 30, 2024, $0 of the principal amount of the Note remains outstanding and all accrued interest has been paid.

On October 8,2021 the Company entered into an agreement with Dr. Brian Koos, MD PhD whereby Dr. Brian Koos would provide services to the Company consisting of :

a) Reviewing existing publications on research being conducted on Checkpoint NR2F6.

b) Identifying the most promising applications for the Company’s technology

c) Drafting a “white paper” on results for 1(b)

d) Making introductions to known experts in appropriate fields identified in 1(b).

Dr. Brian Koos is to be paid compensated $117,000 as total consideration for performing the abovementioned tasks. During the quarter ended December 31, 2021 Dr. Brian Koos was paid the amount of $80,275 and during the quarter ended June 30, 2022 Dr. Brian Koos was paid $36,975. Dr. Brian Koos is the brother of David Koos the Chairman and Chief Executive Officer of the Company.

As of June 30, 2024 the Company is indebted to David R. Koos the Company’s sole officer and director in the amount of $1,708. $710 lent to the Company by Koos is due and payable at the demand of the holder and bear simple interest at a rate of 15% per annum.

On January 13, 2022 Regen Biopharma, Inc. entered into a sublease agreement with BST Partners (“BST”) whereby Regen Biopharma, Inc. would sublet office space located at 4700 Spring Street, Suite 304, La Mesa, California 91942 from BST on a month to month basis for $5,000 per month beginning January 14, 2022. On April 26, 2024 the Company and BST agreed to amend that sublease agreement as follows:

The Company agreed that in addition to the base rent of $5,000 per month to be paid by the Company to BST the Company shall also reimburse BST for any and all shared expenses as such term is defined within the original lease agreement by and between BST and CIF LaMesa LLP beginning January 1, 2024.

BST Partners is controlled by David Koos who serves as the sole officer and director of Regen Biopharma, Inc.

$1,708 lent to the Company by David Koos, the Company’s sole Board Member and Officer, is due and payable at the demand of the holder and bears simple interest at a rate of 15% per annum.

$15,000 lent to the Company by Zander Therapeutics, Inc. is due and payable on May 3. 2025 and bears simple interest at a rate of 10% per annum.

$25,000 lent to the Company by Zander Therapeutics, Inc. is due and payable on June 5. 2025 and bears simple interest at a rate of 10% per annum.

Zander Therapeutics, Inc. and the Company are under common control.

NOTE 7. STOCKHOLDERS’ EQUITY

The stockholders’ equity section of the Company contains the following classes of capital stock as of June 30, 2024:

Common stock, $ 0.0001 par value; 5,800,000,000 shares authorized: 4,373,078 shares issued and outstanding.

With respect to each matter submitted to a vote of stockholders of the Corporation, each holder of Common Stock shall be entitled to cast that number of votes which is equivalent to the number of shares of Common Stock owned by such holder times one (1).

On any voluntary or involuntary liquidation, dissolution or winding up of the Corporation, the holders of the Common Stock shall receive, out of assets legally available for distribution to the Company’s stockholders, a ratable share in the assets of the Corporation.

Preferred Stock, $0.0001 par value, 800,000,000 shares authorized of which 600,000 is designated as Series AA Preferred Stock: 34 shares issued and outstanding as of June 30, 2024, 739,000,000 is designated Series A Preferred Stock of which 429,619 shares are outstanding as of June 30, 2024, 60,000,000 is designated Series M Preferred Stock of which 29,338 shares are outstanding as of June 30, 2024, and 20,000 is designated Series NC stock of which 15,007 shares are outstanding as of June 30, 2024.

The abovementioned shares authorized pursuant to the Company’s certificate of incorporation may be issued from time to time without prior approval of the shareholders. The Board of Directors of the Company shall have the full authority permitted by law to establish one or more series and the number of shares constituting each such series and to fix by resolution full or limited, multiple or fractional, or no voting rights, and such designations, preferences, qualifications, restrictions, options, conversion rights and other special or relative rights of any series of the Stock that may be desired.

Series AA Preferred Stock

On September 15, 2014 the Company filed a CERTIFICATE OF DESIGNATION (“Certificate of Designations”) with the Nevada Secretary of State setting forth the preferences rights and limitations of a newly authorized series of preferred stock designated and known as “Series AA Preferred Stock” (hereinafter referred to as “Series AA Preferred Stock”).

The Board of Directors of the Company have authorized 600,000 shares of the Series AA Preferred Stock, par value $0.0001. With respect to each matter submitted to a vote of stockholders of the Corporation, each holder of Series AA Preferred Stock shall be entitled to cast that number of votes which is equivalent to the number of shares of Series AA Preferred Stock owned by such holder times seven (7). Except as otherwise required by law holders of Common Stock, other series of Preferred issued by the Corporation, and Series AA Preferred Stock shall vote as a single class on all matters submitted to the stockholders.

Series A Preferred Stock

On January 15, 2015 the Company filed a CERTIFICATE OF DESIGNATION (“Certificate of Designations”) with the Nevada Secretary of State setting forth the preferences rights and limitations of a newly authorized series of preferred stock designated and known as “Series A Preferred Stock” (hereinafter referred to as “Series A Preferred Stock”).

The Board of Directors of the Company have authorized 739,000,000 shares of the Series A Preferred Stock, par value $0.0001. With respect to each matter submitted to a vote of stockholders of the Corporation, each holder of Series A Preferred Stock shall be entitled to cast that number of votes which is equivalent to the number of shares of Series A Preferred Stock owned by such holder times one . Except as otherwise required by law holders of Common Stock, other series of Preferred issued by the Corporation, and Series A Preferred Stock shall vote as a single class on all matters submitted to the stockholders.

Holders of the Series A Preferred Stock will be entitled to receive, when, as and if declared by the board of directors of the Company (the “Board”) out of funds legally available therefore, non-cumulative cash dividends of $0.01 per quarter. In the event any dividends are declared or paid or any other distribution is made on or with respect to the Common Stock , the holders of Series A Preferred Stock as of the record date established by the Board for such dividend or distribution on the Common Stock shall be entitled to receive, as additional dividends (the “Additional Dividends”) an amount (whether in the form of cash, securities or other property) equal to the amount (and in the form) of the dividends or distribution that such holder would have received had each share of the Series A Preferred Stock been one share of the Common Stock, such Additional Dividends to be payable on the same payment date as the payment date for the Common Stock.

Upon any liquidation, dissolution, or winding up of the Company, whether voluntary or involuntary (collectively, a “Liquidation”), before any distribution or payment shall be made to any of the holders of Common Stock or any other series of preferred stock, the holders of Series A Preferred Stock shall be entitled to receive out of the assets of the Company, whether such assets are capital, surplus or earnings, an amount equal to $0.01 per share of Series A Preferred (the “Liquidation Amount”) plus all declared and unpaid dividends thereon, for each share of Series A Preferred held by them.

If, upon any Liquidation, the assets of the Company shall be insufficient to pay the Liquidation Amount, together with declared and unpaid dividends thereon, in full to all holders of Series A Preferred, then the entire net assets of the Company shall be distributed among the holders of the Series A Preferred, ratably in proportion to the full amounts to which they would otherwise be respectively entitled and such distributions may be made in cash or in property taken at its fair value (as determined in good faith by the Board), or both, at the election of the Board.

On January 10, 2017 Regen Biopharma, Inc. (“Regen”) filed a CERTIFICATE OF DESIGNATION (“Certificate of Designations”) with the Nevada Secretary of State setting forth the preferences rights and limitations of a newly authorized series of preferred stock designated and known as “Series M Preferred Stock” (hereinafter referred to as “Series M Preferred Stock”).

The Board of Directors of Regen have authorized 60,000,000 shares of the Series M Preferred Stock, par value $0.0001. With respect to each matter submitted to a vote of stockholders of Regen, each holder of Series M Preferred Stock shall be entitled to cast that number of votes which is equivalent to the number of shares of Series M Preferred Stock owned by such holder times one. Except as otherwise required by law holders of Common Stock, other series of Preferred issued by Regen, and Series M Preferred Stock shall vote as a single class on all matters submitted to the stockholders.

The holders of Series M Preferred Stock shall be entitled receive dividends, when, as and if declared by the Board of Directors in accordance with Nevada Law, in its discretion, from funds legally available therefore

On any voluntary or involuntary liquidation, dissolution or winding up of Regen, the holders of the Series M Preferred Stock shall receive, out of assets legally available for distribution to Regen’s stockholders, a ratable share in the assets of Regen.

On March 26, 2021 Regen Biopharma, Inc. ( “Regen”) filed a CERTIFICATE OF DESIGNATION (“Certificate of Designations”) with the Nevada Secretary of State setting forth the preferences rights and limitations of a newly authorized series of preferred stock designated and known as Nonconvertible Series NC Preferred Stock (hereinafter referred to as “Series NC Preferred Stock”).

The Board of Directors of Regen have authorized 20,000 shares of the Series NC Preferred Stock, par value $0.0001. With respect to each matter submitted to a vote of stockholders of Regen, each holder of Series NC Preferred Stock shall be entitled to cast that number of votes which is equivalent to the number of shares of Series NC Preferred Stock owned by such holder times 334. Except as otherwise required by law holders of Common Stock, other series of Preferred issued by Regen, and Series NC Preferred Stock shall vote as a single class on all matters submitted to the stockholders.

The holders of Series NC Preferred Stock shall be entitled receive dividends, when, as and if declared by the Board of Directors in accordance with Nevada Law, in its discretion, from funds legally available therefore

On any voluntary or involuntary liquidation, dissolution or winding up of Regen, the holders of the Series NC Preferred Stock shall receive, out of assets legally available for distribution to Regen’s stockholders, a ratable share in the assets of Regen.

On May 20, 2024 Regen Biopharma, Inc. amended its Certificate of Incorporation adding the following Article 8 which is and reads as follows:

Shares of one class or series of stock may be issued as a share dividend in respect of another class or series.

On May 21 , 2024 the Board of Directors of Regen Biopharma, Inc declared a dividend to all shareholders of record as of June 20, 2024 (“Record Date”) to be paid to shareholders on or about July 1, 2024 such dividend to be payable in shares of the Regen’s authorized but unissued Series A Preferred Stock and to consist of two share of Series A Preferred Stock for every one share of Regen Biopharma, Inc. Common Stock owned as of the Record Date, every one share of Regen Biopharma, Inc. Series A Preferred Stock owned as of the Record Date, every one share of Series AA Preferred Stock owned as of the Record Date, every one share of Series M Preferred Stock owned as of the Record Date and every one share of Series NC Preferred Stock owned as of the Record Date

NOTE 8. INVESTMENT SECURITIES, RELATED PARTY

On June 11, 2018 Regen Biopharma, Inc. was paid a property dividend consisting of 470,588 of the common shares of Zander Therapeutics, Inc.

On November 29, 2018 the Company accepted 725,000 shares of the Series M Preferred stock of Zander Therapeutics, Inc. in satisfaction of prepaid rent and accrued interest owed to the Company collectively amounting to $13,124.

On June 30, 2024 the Company revalued 470,588 of the common shares of Zander Therapeutics, Inc. and 725,000 shares of the Series M Preferred stock of Zander Therapeutics, Inc. based on the following inputs:

Schedule of dividend income
Fair Value of Intellectual Property	$	300,000
Prepaid Expenses		65,661
Due from Employee		0
Note Receivable		40,000
Accrued Interest Receivable		35,000
Investment Securities		258,255
Convertible Note Receivable		10,000
Accounts Payable		30,563
Notes Payable		400,000
Accrued Expenses Related Parties		162,011
Notes Payable Related Party		0
Accrued Expenses		647,072
Enterprise Value		1,948,562
Less: Total Debt		(1,239,646	)
Portion of Enterprise Value Attributable to Shareholders		708,916
Fair Value Per Share	$	0.02

The abovementioned constitute the Company’s sole related party investment securities as of June 30, 2024.

As of June 30, 2024:

	Schedule of comprehensive income
470,588 Common Shares of Zander Therapeutics, Inc.

	Basis		Fair Value		Total Unrealized Gains		Net Unrealized Gain or (Loss) realized during the quarter ended June 30, 2024
$	5,741	$	6,496	$	755	$	(0	)

725,000 Series M Preferred of Zander Therapeutics, Inc.

	Basis		Fair Value		Total Unrealized Loss			Net Unrealized Gain or (Loss) realized during the quarter ended June 30, 2024
$	13,124	$	11,238	$	(1,866	)	$	(0	)

NOTE 9. STOCK TRANSACTIONS

On April 3, 2024 the Company issued 52,763 common shares for cash consideration of $25,326.

On May 2, 2024 the Company issued 20,068 Series A Preferred shares for nonemployee services .

On May 29, 2024 the Company issued 66,185 common shares for cash consideration of $30,000.

On June 7, 2024 the Company issued 62,207 common shares for cash consideration of $30,000.

On June 20, 2024 the Company issued 75,301 common shares for cash consideration of $50,000.

NOTE 10. SUBSEQUENT EVENTS

On May 21 , 2024 the Board of Directors of Regen Biopharma, Inc.(“Regen”) declared a dividend to all shareholders of record as of June 20,2024 (“Record Date”) to be paid to shareholders on or about July 1, 2024 such dividend to be payable in shares of the Regen’s authorized but unissued Series A Preferred Stock and to consist of two share of Series A Preferred Stock for every one share of Regen Biopharma, Inc. Common Stock owned as of the Record Date, every one share of Regen Biopharma, Inc. Series A Preferred Stock owned as of the Record Date, every one share of Series AA Preferred Stock owned as of the Record Date, every one share of Series M Preferred Stock owned as of the Record Date and every one share of Series NC Preferred Stock owned as of the Record Date.

On July 3, 2024 9,694,152 Series A Preferred Shares were issued as a dividend to the Shareholders of Record.

On July 12, 2024 the Company sold 135,242 common shares to Coventry pursuant to the terms and conditions of the Equity Line Agreement for total cash consideration of $28,125.

Item 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

CERTAIN FORWARD-LOOKING INFORMATION

Information provided in this Quarterly report on Form 10Q may contain forward-looking statements within the meaning of Section 21E or Securities Exchange Act of 1934 that are not historical facts and information. These statements represent the Company’s expectations or beliefs, including, but not limited to, statements concerning future and operating results, statements concerning industry performance, the Company’s operations, economic performance, financial conditions, margins and growth in sales of the Company’s products, capital expenditures, financing needs, as well assumptions related to the forgoing. For this purpose, any statements contained in this Quarterly Report that are not statement of historical fact may be deemed to be forward-looking statements. These forward-looking statements are based on current expectations and involve various risks and uncertainties that could cause actual results and outcomes for future periods to differ materially from any forward-looking statement or views expressed herein. The Company’s financial performance and the forward-looking statements contained herein are further qualified by other risks including those set forth from time to time in the documents filed by the Company with the Securities and Exchange Commission. All references to” We”, “Us”, “Company” or the “Company” refer to Regen BioPharma, Inc.

As of June 30, 2024 we had cash of $61,849 and as of September 30, 2023 we had cash of $121,037. The decrease in cash of approximately 49% is primarily attributable to cash expended in the operation of the Company’s business as well as payments of principal amounts due on Notes Payable , Convertible Notes Payable ( Related Party) and accrued interest due on Convertible Notes Payable ( Related Party) offset primarily by $535,560 paid to the Company from sales of common stock of the Company for cash as well as borrowings from related parties totaling $40,998 during the quarter ended June 30, 2024 .

As of June 30, 2024 we had Accounts Receivable, Related Party of $61,647 and as of September 30, 2023 we had Accounts Receivable, Related Party of $0. Accounts Receivable, Related Party as of June 30, 2024 consists of fees accrued but not yet paid pursuant to a license granted to Zander Therapeutics, Inc. by Regen Biopharma, Inc. Zander Therapeutics, Inc. and the Company are under common control.

As of June 30, 2024 we had Prepaid Expenses of $10,921 and as of September 30, 2023 we had Prepaid Expenses of $0. Prepaid Expenses of $32,364 as of June 30, 2024 is attributable to an overpayment of $200 paid to a patent attorney as well as the payment of 20,068 shares of the Company’s Series A Preferred stock valued at $13,044 paid to an independent consultant for services to be provided for a period of one year commencing on April 26, 2024.

As of June 30, 2024 we had Investment Securities (Related Party) of $17,733 and as of September 30, 2023 we had Investment Securities (Related Party) of $222,580. During the nine months ended June 30, 2024 the Company revalued its owned shares of Zander Therapeutics, Inc. resulting in the recognition of a decrease in fair value of 92.3% as compared to September 30, 2023.

As of June 30, 2024 we had Notes Payable of $218,230 and as of September 30, 2023 we had Notes Payable of $245,324. The reduction in Notes Payable of approximately 11% is attributable to repayment of $81,500 of outstanding principal indebtedness during the nine months ended June 30, 2024 offset by Notes issued by the Company during the quarter ended June 30, 2024 of (a) $40,000 to Zander Therapeutics, Inc. (an entity under common control with the Company) and
(b) $998 to the Company’s Chief Executive Officer as well as the recognition of $13,045 of amortization of interest expenses attributable to an Original Issue Discount recognized in connection with a Promissory Note issued to Coventry Enterprises in the original principal amount of $175,000.

As of June 30, 2024 we had Accrued Interest Payable of $359,970 and as of September 30, 2023 we had Accrued Interest Payable if $342,588. The increase of approximately 5% is attributable to interest expense accrued but unpaid during the nine months ended June 30, 2024.

As of June 30, 2024 we had Convertible Notes Payable, Related Parties of $0 and as of September 30, 2023 we had Convertible Notes Payable, Related Parties of $10,000. $10,000 due and payable to Zander Therapeutics, Inc. was paid during the quarter ended March 31, 2024. Zander Therapeutics, Inc. and the Company are under common control.

As of June 20, 2024 we had Unearned Income of $1,496,811and as of September 30,2023 we had Unearned Income of $1,591,731. Unearned Income represents that portion of $1,905,000 of license fees paid during the quarter ended June 30, 2021 to be recognized as revenue over the 15 year term of the licenses granted in accordance with ASC 606. The decrease of approximately 6% is attributable to the recognition by the Company of $94,920 of licensing revenue over the nine months ended June 30, 2024. .

Revenues from continuing operations were $59,065 for the quarter ended June 30, 2024 and $59,065 for the same period ended 2023. $27,425 of revenue from related parties recognized during the three months ended June 30, 2024 and June 30, 2023 consisted of anniversary expense receivable pursuant to a license granted by the Company to Zander Therapeutics, Inc. and minimum royalties recognized during the three months ended March 31, 2023 and 2024 respectively pursuant to the same license. $31,640 of revenue recognized during the three months ended June 30, 2024 were recognized pursuant to licenses granted to Oncology Pharma,Inc. and $31,640 of revenue was recognized during the quarter ended June 30 , 2023 pursuant to those same licenses.

The Company recognized an Operating Loss of $107,966 during the quarter ended June 30, 2024 whereas the Company recognized an Operating Loss of $85,155 for the same period ended 2023. The disparity in Operating Losses is primarily attributable to greater Consulting Expenses recognized during the quarter ended June 30, 2024 as compared to the same quarter ended 2023. The Company recognized a Net Loss of $130,120 during the quarter ended June 30, 2024 whereas the Company recognized a Net Loss of $99,218 during the quarter ended June 30, 2023. The disparity is primarily attributable to the same factors which contributed to the disparity in the Operating Loss recognized during the quarter ended 2024 as compared to the same period ended 2023.

Revenues from continuing operations were $177,194 for the nine months ended June 30, 2024 and $177,194 for the same period ended 2023. $82,274 of revenue from related parties recognized during the nine months ended June 30, 2024 and June 30, 2023 consisted of anniversary expense receivable pursuant to a license granted by the Company to Zander Therapeutics, Inc. and minimum royalties recognized during the nine months ended June 30, 2023 and 2024 respectively pursuant to the same license. $94,920 of revenue recognized during the nine months ended June 30, 2024 were recognized pursuant to licenses granted to Oncology Pharma,Inc. and $94,920 of revenue was recognized during the nine months ended June 30 , 2023 pursuant to those same licenses.

The Company recognized an Operating Loss of $331,819 during the nine months ended June 30, 2024 whereas the Company recognized an Operating Loss of $627,863 for the same period ended 2023. The disparity in Operating Losses is primarily attributable to greater Research and Development and Consulting Expenses recognized during the nine months ended June 30, 2023 as compared to the same period ended 2024. The Company recognized a Net Loss of $ 602,353 during the nine months ended June 30, 2024. The Company recognized Net Income of $1,481,534 during the nine months ended June 30, 2023 primarily attributable to the recognition of $2,151,755 during the nine months ended June 30, 2023.

As of June 30, 2024 we had $61,849 in cash on hand and current liabilities of $5,327,862 such liabilities materially consisting of Accounts Payable, Notes Payable, Convertible Notes Payable, Derivative Liability Recognized, Unearned Income and Accrued Expenses. We feel we will not be able to satisfy our cash requirements over the next twelve months and shall be required to seek additional financing.

On September 12, 2023 the Company entered into a common stock purchase agreement (the “Equity Line Agreement”) with Coventry Enterprises LLC ( “Coventry”) providing for an equity financing facility (the “Equity Line”). The Equity Line Agreement provides that upon the terms and subject to the conditions in the Equity Line Agreement, Coventry is committed to purchase up to Ten Million Dollars ($10,000,000) of shares of common stock, $0.0001 par value per share (the “Common Stock”), over the 36-month term of the Equity Line Agreement (the “Total Commitment”).

The maximum number of shares of Common Stock requested to be purchased pursuant to any single Draw Down Notice cannot exceed the lesser of (i) 200% of the Average Daily Traded Value ( as such term is defined in the Equity Line Agreement) during the ten business days immediately preceding the Drawdown Notice Date or (ii) $250,000. The Company is prohibited from delivering a Draw Down Notice if the sale of shares of Common Stock pursuant to the Draw Down Notice would cause the Company to issue and sell to Coventry or Coventry to acquire or purchase an aggregate number of shares of Common Stock that would result in Coventry beneficially owning more than 4.99% of the issued and outstanding shares of Common Stock of the Company.

During the quarter ended December 31, 2023 the Company sold 244,199 common shares to Coventry pursuant to the terms and conditions of the Equity Line Agreement for total cash consideration of $212,297.

During the quarter ended March 31, 2024 the Company sold 364,057 common shares to Coventry pursuant to the terms and conditions of the Equity Line Agreement for total cash consideration of $187,973.

During the quarter ended June 30, 2024 the Company sold 258,456 common shares to Coventry pursuant to the terms and conditions of the Equity Line Agreement for total cash consideration of $135,327.

On July 12, 2024 the Company sold 135,242 common shares to Coventry pursuant to the terms and conditions of the Equity Line Agreement for total cash consideration of $28,125.

As of June 30 2024 the Company was not party to any binding agreements which would commit Regen to any material capital expenditures.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

As a smaller reporting company, as defined by Rule 229.10(f) (1) of Regulation S-K, we are not required to provide the information required by this Item. We have chosen to disclose, however, that we have not engaged in any transactions, issued or bought any financial instruments or entered into any contracts that are required to be disclosed in response to this item.

Item 4. Controls and Procedures.

Evaluation of Disclosure Controls and Procedures

As of the end of the period covered by this report, the Company carried out an evaluation, under the supervision and with the participation of David Koos, who is the Company’s Principal Executive Officer and Principal Financial Officer of the effectiveness of the design and operation of the Company’s disclosure controls and procedures. The Company’s disclosure controls and procedures are designed to provide a reasonable level of assurance of achieving the Company’s disclosure control objectives. The Company’s Principal Executive Officer and Principal Financial Officer have concluded that the Company’s disclosure controls and procedures are, in fact, effective at this reasonable assurance level as of the period covered.

Changes in Internal Controls over Financial Reporting

In connection with the evaluation of the Company’s internal controls during the period commencing on April 1, 2024 and ending on June 30, 2024, David Koos, who serves as the Company’s Principal Executive Officer , Principal Financial Officer has determined that there were no changes to the Company’s internal controls over financial reporting that have been materially affected, or is reasonably likely to materially effect, the Company’s internal controls over financial reporting.

PART II - OTHER INFORMATION

Item 1. Legal Proceedings.

None

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

On April 2, 2024 the Company issued 20,068 of its Series A Preferred Shares to an independent consultant as consideration for services.

The abovementioned securities were issued pursuant to Section 4(a) (2) of the securities Act of 1933, as amended (the “Act”). No underwriters were retained to serve as placement agents for the sale. The securities were sold directly through our management. No commission or other consideration was paid in connection with the sale of the securities. There was no advertisement or general solicitation made in connection with this Offer and Sale of securities.

Item 5. Other Information

On May 21 , 2024 the Board of Directors of Regen Biopharma, Inc.(“Regen”) declared a adopteddividend to all shareholders of record as of June 20,2024 (“Record Date”) to be paid to shareholders on or about July 1, 2024 such dividend to be payable in shares of the Regen’s authorized but unissued Series A Preferred Stock and to consist of two share of Series A Preferred Stock for every one share of Regen Biopharma, Inc. Common Stock owned as of the Record Date, every one share of Regen Biopharma, Inc. Series A Preferred Stock owned as of the Record Date, every one share of Series AA Preferred Stock owned as of the Record Date, every one share of Series M Preferred Stock owned as of the Record Date and every one share of Series NC Preferred Stock owned as of the Record Date.

On July 3 2024 9,694,152 Series A Preferred Shares were issued as a dividend to the Shareholders of Record.

Item 6. Exhibit Index

Exhibit No.	Description
31.1	CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANESE-OXLEY ACT OF 2002
31.2	CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO SECTION 302 OF THE SARBANESE-OXLEY ACT OF 2002
32.1	CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO 18 U.S.C SECTION 1350 AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
32.2	CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S.C SECTION 1350 AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
10.1	NOTE PAYABLE ZANDER $15,000
10.2	NOTE PAYABLE ZANDER $25,000

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Regen Biopharma, Inc.

By: /s/ David R. Koos

Name: David R. Koos

Title: Chairman, Chief Executive Officer

Date: August 13, 2024

Regen Biopharma, Inc.

By: /s/ David R. Koos

Name: David R. Koos

Title: Acting Chief Financial Officer, Director

Date: August 13, 2024

CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, David R. Koos certify that:

1. I have reviewed this quarterly report on Form 10-Q for the period ended June 30, 2024 of Regen Biopharma, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal controls over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant’s, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles:

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent function):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Dated: August 13, 2024	By:	/s/ David R. Koos
		David R. Koos
		Chief Exeuctive Officer

CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, David R. Koos certify that:

1. I have reviewed this quarterly report on Form 10-Q for the period ended June 30, 2024 of Regen Biopharma, Inc.;

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Dated: August 13, 2024	By:	/s/ David R. Koos
		David R. Koos
		Chief Financial Officer

CERTIFICATION OF CHIEF EXECUTIVE OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO SECTION 906

OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Regen Biopharma, Inc. on Form 10-Q for the period ended June 30, 2024 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, David R. Koos, Chief Financial Officer certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge and belief:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: August 13, 2024	By:	/s/ David R. Koos
		David R. Koos
		Chief Executive Officer

CERTIFICATION OF CHIEF FINANCIAL OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO SECTION 906

OF THE SARBANES-OXLEY ACT OF 2002

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: August 13, 2024	By:	/s/ David R. Koos
		David R. Koos
		Chief Financial Officer

Exhibit 10.1

PROMISSORY NOTE (“NOTE”) - 10% SIMPLE INTEREST MAY 3, 2024

$15,000

September 20, 2021

For VALUE RECEIVED, REGEN BIOPHARMA, INC. (“Borrower”) promises to pay to Zander Therapeutics, Inc. (“Lender”) the principal sum of Fifteen Thousand Dollars ($15,000) with accrued simple interest at the rate of 10% percent per annum on the balance. The said principal and accrued interest shall be payable in lawful money of the United States of America on May 3, 2025. This Note may be prepaid in whole or in part at any time without premium or penalty. The Borrower hereby waives any notice of the transfer of this Note by the Lender or by any subsequent holder of this Note, agrees to remain bound by the terms of this Note subsequent to any transfer, and agrees that the terms of this Note may be fully enforced by any subsequent holder of this Note. All terms and conditions of this Note shall be interpreted under the laws of the state of California and venue shall be the state of California.

REGEN BIOPHARMA, INC.

By: /s/ David Koos

Its: Chairman and CEO

Accepted By:

ZANDER THERAPEUTICS, INC.

By: /s/ David Koos
Its: Chairman and CEO

Exhibit 10.2

PROMISSORY NOTE (“NOTE”) - 10% SIMPLE INTEREST JUNE 5, 2024

$25,000

September 20, 2021

For VALUE RECEIVED, REGEN BIOPHARMA, INC. (“Borrower”) promises to pay to Zander Therapeutics, Inc. (“Lender”) the principal sum of Twenty Five Thousand Dollars ($25,000) with accrued simple interest at the rate of 10% percent per annum on the balance. The said principal and accrued interest shall be payable in lawful money of the United States of America on June 5, 2025. This Note may be prepaid in whole or in part at any time without premium or penalty. The Borrower hereby waives any notice of the transfer of this Note by the Lender or by any subsequent holder of this Note, agrees to remain bound by the terms of this Note subsequent to any transfer, and agrees that the terms of this Note may be fully enforced by any subsequent holder of this Note. All terms and conditions of this Note shall be interpreted under the laws of the state of California and venue shall be the state of California.

REGEN BIOPHARMA, INC.

By: /s/David Koos

Its: Chairman and CEO

Accepted By:

ZANDER THERAPEUTICS, INC.

By: /s/ Davis Koos
Its: Chairman and CEO

Cover - shares	9 Months Ended
Cover - shares	Jun. 30, 2024	Jul. 17, 2024
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Jun. 30, 2024
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2024
Current Fiscal Year End Date	--09-30
Entity File Number	333-191725
Entity Registrant Name	REGEN BIOPHARMA, INC.
Entity Central Index Key	0001589150
Entity Tax Identification Number	45-5192997
Entity Incorporation, State or Country Code	NV
Entity Address, Address Line One	4700 Spring Street
Entity Address, Address Line Two	St 304
Entity Address, City or Town	La Mesa
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	91942
City Area Code	619
Local Phone Number	722-5505
Entity Current Reporting Status	Yes
Entity Interactive Data Current	No
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		4,508,320

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)	Jun. 30, 2024	Sep. 30, 2023
CURRENT ASSETS
Cash	$ 61,849	$ 121,037
Accounts Receivable, Related Party	67,147	0
Note Receivable, Related Party		0
Prepaid Expenses	10,921	0
Prepaid Rent	12,500	10,000
Total Current Assets	152,417	131,037
OTHER ASSETS
Investment Securities, Related Party	17,733	222,580
Total Other Assets	17,733	222,580
Total Assets	170,150	353,617
Current Liabilities:
Accounts payable	29,416	29,674
Notes Payable	218,230	95,710
Accrued payroll taxes	4,241	4,241
Accrued Interest	359,970	342,588
Accrued Payroll	1,256,630	1,256,630
Other Accrued Expenses	41,423	41,423
Bank Overdraft	1,000	1,000
Due to Investor	20,000	20,000
Unearned Income	1,496,811	1,591,731
Unearned Income (Related Party)	0	15,126
Derivative Liability	1,400,261	1,400,000
Convertible Notes Payable Less unamortized discount	499,880	499,880
Convertible Notes Payable, Related Parties Less unamortized discount	0	10,000
Total Current Liabilities	5,327,862	5,308,003
Long Term Liabilities:
Notes Payable	0	149,614
Total Long Term Liabilities	0	149,614
Total Liabilities	5,327,862	5,457,617
STOCKHOLDERS' EQUITY (DEFICIT)
Common Stock ($.0001 par value) 500,000,000 shares authorized; 5,800,000,000 authorized and 4,373,078 issued and outstanding as of June, 2024 and 3,506,366 shares issued and outstanding as of September 30, 2023.	439	352
Additional Paid in capital	14,456,692	13,908,141
Contributed Capital	736,326	736,326
Retained Earnings (Deficit)	(20,351,216)	(19,748,863)
Total Stockholders' Equity (Deficit)	(5,157,712)	(5,104,000)
TOTAL LIABILITIES & STOCKHOLDERS' EQUITY (DEFICIT)	170,150	353,617
Series A Preferred Stock [Member]
STOCKHOLDERS' EQUITY (DEFICIT)
Preferred stock, value	42	40
Series AA Preferred Stock [Member]
STOCKHOLDERS' EQUITY (DEFICIT)
Preferred stock, value	0	0
Series M Preferred Stock [Member]
STOCKHOLDERS' EQUITY (DEFICIT)
Preferred stock, value	3	3
Series NC Preferred Stock [Member]
STOCKHOLDERS' EQUITY (DEFICIT)
Preferred stock, value	$ 2	$ 2

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Jun. 30, 2024	Sep. 30, 2023
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	500,000,000	5,800,000,000
Common stock, shares issued	4,373,078	3,506,366
Common stock, shares outstanding	4,373,078	3,506,366
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	800,000,000	800,000,000
Series A Preferred Stock [Member]
Preferred stock, shares authorized	739,000,000	739,000,000
Preferred stock, shares outstanding	429,619	409,551
Series AA Preferred Stock [Member]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	600,000	600,000
Preferred stock, shares outstanding	34	34
Series M Preferred Stock [Member]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	60,000,000	60,000,000
Preferred stock, shares outstanding	29,338	29,338
Series NC Preferred Stock [Member]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	20,000	20,000
Preferred stock, shares outstanding	15,007	15,007

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
REVENUES
Revenues	$ 31,640	$ 31,640	$ 94,920	$ 94,920
Revenues, Related Party	27,425	27,425	82,274	82,274
TOTAL REVENUES	59,065	59,065	177,194	177,194
COST AND EXPENSES
Research and Development	32,500	45,001	120,161	176,960
General and Administrative	16,492	9,262	38,298	36,660
Consulting and Professional Fees	95,539	74,957	295,839	546,437
Rent	22,500	15,000	54,715	45,000
Total Costs and Expenses	167,031	144,220	509,012	805,057
OPERATING INCOME (LOSS)	(107,966)	(85,155)	(331,819)	(627,863)
OTHER INCOME & (EXPENSES)
Interest Expense	(17,554)	(14,063)	(52,382)	(43,507)
Interest Expense attributable to Amortization of Discount	(4,339)	0	(13,045)
Unrealized Gain ( Loss) on sale of Investment Securities			(204,847)
Derivative Income (Expense)	(261)	0	(261)	2,151,755
Gain (Loss) on Extinguishment Convertible Debt				1,150
TOTAL OTHER INCOME (EXPENSE)	(22,154)	(14,063)	(270,534)	2,109,397
NET INCOME (LOSS)	(130,120)	(99,218)	(602,353)	1,481,534
NET INCOME (LOSS) attributable to common shareholders	$ (117,108)	$ (99,218)	$ (602,353)	$ 1,303,750
BASIC EARNINGS (LOSS) PER SHARE	$ (0.03)	$ (0.03)	$ (0.15)	$ 0.39
FULLY DILUTED EARNINGS (LOSS) PER SHARE	$ (0.03)	$ (0.03)	$ (0.15)	$ 0.39
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING - BASIC	4,213,611	3,381,366	3,974,434	3,370,012
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING - DILUTED	4,213,611	3,381,366	3,974,434	3,370,012

CONDENSED CONSOLIDATED STATEMENT OF SHAREHOLDERS' EQUITY (DEFICIT) (unaudited) - USD ($)	Preferred Stock Series A [Member]	Preferred Stock Series A A [Member]	Preferred Stock Series N C [Member]	Common Stock [Member]	Series M Preferred Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Contributed Capital [Member]	Total
Beginning balance, value at Sep. 30, 2022	$ 28	$ 0		$ 335	$ 3	$ 12,132,620	$ (20,905,369)	$ 736,326	$ (8,036,059)
Beginning balance, shares at Sep. 30, 2022	293,053	34	7	3,354,886	29,338
Net Income (Loss)							1,635,730		1,635,730
Preferred Shares Issued for Nonemployee Services	$ 1					299,999			300,000
Preferred Shares Issued for Nonemployee Services, shares	6,667
Preferred Shares Issued for Debt	$ 7					761,493			761,500
Preferred Shares Issued for Debt, shares	70,114
Preferred Shares Issued for Interest	$ 4					380,258			380,262
Preferred Shares Issued for Interest, shares	35,012
Common Shares Issued For Interest				$ 1		25,368			25,369
Common Shares Issued For Interest, shares				11,279
Preferred Shares Issued for Nonemployee Services	$ 0					48,372			48,372
Preferred Shares Issued for Nonemployee Services, shares	1,112
Ending balance, value at Dec. 31, 2022	$ 40	$ 0		$ 337	$ 3	13,648,107	(19,269,640)	736,326	(4,884,827)
Ending balance, shares at Dec. 31, 2022	405,958	34	7	3,366,165	29,338
Common Shares issued pursuant to round up provision
March 6,2023 reverse stock split				$ 2		(2)			0
March 6,2023 reverse stock split, shares				15,201
Preferred Shares issued pursuant to round up provision
March 6,2023 reverse stock split
March 6,2023 reverse stock split, shares	3,593
Preferred Shares issued for accrued salaries			2			10,048			10,050
Preferred Shares issued for accrued salaries, shares				15,000
Net Income (Loss)							(54,978)		(54,978)
Ending balance, value at Mar. 31, 2023	$ 40	$ 0	$ 2	$ 339	$ 3	13,658,153	(19,324,617)	736,326	(4,929,755)
Ending balance, shares at Mar. 31, 2023	409,551	34	15,007	3,381,366	29,338
Net Income (Loss)							(99,218)		(99,218)
Ending balance, value at Jun. 30, 2023	$ 40	$ 0	$ 2	$ 339	$ 3	13,658,153	(19,423,836)	736,326	(5,028,973)
Ending balance, shares at Jun. 30, 2023	409,551	34	15,007	3,381,366	29,338
Beginning balance, value at Sep. 30, 2023	$ 40	$ 0	$ 2	$ 352	$ 3	13,908,141	(19,748,863)	736,326	(5,104,000)
Beginning balance, shares at Sep. 30, 2023	409,551	34	15,007	3,506,366	29,338
Common Shares issued for Cash				$ 2		22,724			22,726
Common Shares issued for Cash, shares				16,710
Common Shares issued for Cash				$ 4		46,088			46,091
Common Shares issued for Cash, shares				35,785
Common Shares issued for Cash				$ 3		38,202			38,205
Common Shares issued for Cash, shares				31,732
Common Shares issued for Cash				$ 3		32,626			32,629
Common Shares issued for Cash, shares				33,989
Common Shares issued for Cash				$ 4		38,097			38,101
Common Shares issued for Cash, shares				43,297
Common Shares issued for Cash				$ 8		34,535			34,543
Common Shares issued for Cash, shares				82,686
Net Income (Loss)							(349,760)		(349,760)
Ending balance, value at Dec. 31, 2023	$ 40	$ 0	$ 2	$ 376	$ 3	14,120,412	(20,098,623)	736,326	(5,241,463)
Ending balance, shares at Dec. 31, 2023	409,551	34	15,007	3,750,565	29,338
Net Income (Loss)							(122,473)		(122,473)
1/3/2024				$ 9		39,629			39,638
Common Shares issued for Cash, shares				94,883
1/10/2024				$ 8		44,288			44,297
Common Shares issued for Cash, shares				82,643
2/2/2024				$ 4		19,609			19,614
Common Shares issued for Cash, shares				40,229
2/21/2024				$ 5		32,356			32,362
Common Shares issued for Cash, shares				52,569
3/6/2023				$ 4		25,278			25,282
Common Shares issued for Cash, shares				44,503
3/20/2024				$ 5		26,776			26,781
Common Shares issued for Cash, shares				49,230
Ending balance, value at Mar. 31, 2024	$ 40	$ 0	$ 2	$ 413	$ 3	14,308,349	(20,221,096)	736,326	(5,175,963)
Ending balance, shares at Mar. 31, 2024	409,551	34	15,007	4,114,622	29,338
Net Income (Loss)							(130,120)		(130,120)
4/3/2024						25,321			25,326
Common Shares issued for Cash, shares				52,763
5/2/2024	$ 2					13,042			13,044
Common Shares issued for Cash, shares	20,068
5/29/2024				$ 7		29,993			30,000
Common Shares issued for Cash, shares				68,185
6/7/2024				$ 6		29,994			30,000
Common Shares issued for Cash, shares				62,207
6/20/2024				$ 8		49,992			50,000
Common Shares issued for Cash, shares				75,301
Ending balance, value at Jun. 30, 2024	$ 42	$ 0	$ 2	$ 439	$ 3	$ 14,456,692	$ (20,351,216)	$ 736,326	$ (5,157,712)
Ending balance, shares at Jun. 30, 2024	429,619	34	15,007	4,373,078	29,338

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) - USD ($)	9 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
CASH FLOWS FROM OPERATING ACTIVITIES
Net Income (loss)	$ (602,353)	$ 1,481,534
Adjustments to reconcile net Income to net cash
Preferred Stock issued as compensation	2,324	348,372
Increase (Decrease) in Interest expense attributable to amortization of Discount	13,045
Increase (Decrease) in Accounts Payable	(258)	604
(Increase) Decrease in Accounts Receivable	(67,148)	197,725
Increase (Decrease) in accrued Expenses	17,383	43,507
(Increase) Decrease in Prepaid Expenses	(2,300)	25,570
Increase(Decrease) in Contributed Capital	0
Increase ( Decrease) in Derivative Expense	261	(2,151,755)
Increase ( Decrease) in Unearned Income	(110,047)	(94,920)
(Gain) Loss on forgiveness of Debt	0	(1,150)
Unrealized Loss(Gain) on Investment Securities	204,847
Net Cash Provided by (Used in) Operating Activities	(544,246)	(150,512)
CASH FLOWS FROM FINANCING ACTIVITIES
Increase (Decrease) in Convertible Notes Payable	(10,000)
Increase (Decrease) in Notes Payable	(40,502)	100,000
Increase ( Decrease) in Common Stock issued for cash	535,560
Net Cash Provided by (Used in) Financing Activities	485,058	100,000
Net Increase (Decrease) in Cash	(59,188)	(50,512)
Cash at Beginning of Period	121,037	51,204
Cash at End of Period	61,849	692
Supplemental Disclosure of Noncash investing and financing activities:
Preferred Shares Issued for Debt	0	761,500
Common shares Issued for Interest	0	25,369
Preferred Shares issued for Interest	$ 0	$ 380,262

Pay vs Performance Disclosure - USD ($)	3 Months Ended		9 Months Ended
Pay vs Performance Disclosure - USD ($)	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Pay vs Performance Disclosure [Table]
Net Income (Loss)	$ (130,120)	$ (99,218)	$ (602,353)	$ 1,481,534

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

9 Months Ended

Jun. 30, 2024

Accounting Policies [Abstract]

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

NOTE 1. ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

The Company was organized April 24, 2012 under the laws of the State of Nevada

A. BASIS OF ACCOUNTING

B. PRINCIPLES OF CONSOLIDATION

Schedule of Derivative liability
Schedule of Derivative liability
Risk Free Interest Rate	5.39	%
Expected Term	(3.53) – (4.16) Yrs
Expected Volatility	1128.35	%
Expected Dividends

H. INCOME TAXES

The Company generated a deferred tax credit through net operating loss carry forward. However, a valuation allowance of 100% has been established.

Interest and penalties on tax deficiencies recognized in accordance with ACS accounting standards are classified as income taxes in accordance with ASC Topic 740-10-50-19.

I. BASIC EARNINGS (LOSS) PER SHARE

Basic net loss per share amounts is computed by dividing the net income by the weighted average number of common shares outstanding.

J. ADVERTISING

Costs associated with advertising are charged to expense as incurred. Advertising expenses were $0 for the quarters ended June 30, 2023 and June 30, 2024.

K. NOTES RECEIVABLE

Notes receivable are stated at cost, less impairment, if any.

L. REVENUE RECOGNITION

M. INTEREST RECEIVABLE

Interest receivable is stated at cost, less impairment, if any.

RECENT ACCOUNTING PRONOUNCEMENTS

9 Months Ended

Jun. 30, 2024

Accounting Changes and Error Corrections [Abstract]

RECENT ACCOUNTING PRONOUNCEMENTS

NOTE 2. RECENT ACCOUNTING PRONOUNCEMENTS

The amount the reporting entity agreed to pay on the basis of its arrangement among co-obligors.

Any additional amounts the reporting entity expects to pay on behalf of its co-obligors.

GOING CONCERN

9 Months Ended

Jun. 30, 2024

Organization, Consolidation and Presentation of Financial Statements [Abstract]

GOING CONCERN

NOTE 3. GOING CONCERN

The Company issued Coventry 125,000 shares of its Common Stock in connection with the Equity Line Agreement.

Coventry has agreed that:

(a)

for so long as the market price of the Company’s common stock is above $1.25 per share and

(b)

the Company is in full compliance with all agreements entered into with Coventry and

(c)

NOTES PAYABLE

9 Months Ended

Jun. 30, 2024

Debt Disclosure [Abstract]

NOTES PAYABLE

NOTE 4. NOTES PAYABLE

(a) RELATED PARTY

Notes payable related party
	As of June 30, 2024
David Koos	$	1,708
Zander Therapeutics, Inc.	$	40,000
Total:	$	41,708

$1,708 lent to the Company by David Koos is due and payable at the demand of the holder and bears simple interest at a rate of 15% per annum.

$15,000 lent to the Company by Zander Therapeutics, Inc. is due and payable on May 3. 2025 and bears simple interest at a rate of 10% per annum.

$25,000 lent to the Company by Zander Therapeutics, Inc. is due and payable on June 5. 2025 and bears simple interest at a rate of 10% per annum.

Zander Therapeutics, Inc. and the Company are under common control.

(b) NON RELATED PARTY As of March 31, 2024

Schedule of non related party
Bostonia Partners, Inc	$	48,500
Coventry Enterprises LLC	$	140,000
Total:	$	188,500

$48,500 lent to the Company by Bostonia Partners, Inc is due and payable on March 10, 2024 and bears simple interest at a rate of 10% per annum.

CONVERTIBLE NOTES PAYABLE

9 Months Ended

Jun. 30, 2024

Convertible Notes Payable

CONVERTIBLE NOTES PAYABLE

NOTE 5. CONVERTIBLE NOTES PAYABLE

“Transaction Event” shall mean either of:

(a) The sale by the Company of the Company’s proprietary NR2F6 intellectual property to an unaffiliated third party

As of June 30, 2024 $100,000 of the principal amount of the Note remains outstanding.

Upon closing of a Transaction Event the Lender shall receive 0 .10% ( one tenth of one percent) of the consideration actually received by the Company from an unaffiliated third party as a result of the closing of a Transaction Event.

“Transaction Event” shall mean either of:

(a) The sale by the Company of the Company’s proprietary NR2F6 intellectual property to an unaffiliated third party

As of June 30, 2024 $50,000 of the principal amount of the Note remains outstanding.

The Lender shall have the right from time to time to convert all or a part of the outstanding and unpaid principal amount of this Note into fully paid and non- assessable shares of Common Stock and/or Series A Preferred Stock, as such Stock exists on the Issue Date, or any shares of capital stock or other securities of the Company into which such Stock shall hereafter be changed or reclassified at a conversion price of $18.75 per share.

As of June 30, 2024 $50,000 of the principal amount of the Note remains outstanding

(iii) That date which is twenty four (24) months subsequent to the date of execution of this Note.

The warrants shall be exercisable:

As of June 30, 2024 $200,000 of the principal amount of the Note remains outstanding.

The Company values the embedded derivative using the Black-Scholes pricing model and a derivative liability of $800,149 was recognized by the Company as of June 30, 2024.

(iv) One day subsequent to a “Transaction Event”)

Transaction Event” shall mean either of:

(a) The sale by the Company or by KCL Therapeutics , Inc. of the Company’s proprietary NR2F6 intellectual property to an unaffiliated third party

(v) That date which is twenty four (24) months subsequent to the date of execution of this Note.

The warrants shall be exercisable:

As of June 30, 2024 $100,000 of the principal amount of the Note remains outstanding.

The Company values the embedded derivative using the Black-Scholes pricing model and a derivative liability of $400,075 was recognized by the Company as of June 30, 2024.

(iv) One day subsequent to a “Transaction Event”)

Transaction Event” shall mean either of:

(a) The sale by the Company or by KCL Therapeutics , Inc. of the Company’s proprietary NR2F6 intellectual property to an unaffiliated third party

(v) That date which is twenty four (24) months subsequent to the date of execution of this Note.

The warrants shall be exercisable:

As of June 30, 2024, $50,000 of the principal amount of the Note remains outstanding.

The Company values the embedded derivative using the Black-Scholes pricing model and a derivative liability of $200,037 was recognized by the Company as of June 30, 2024.

RELATED PARTY TRANSACTIONS

9 Months Ended

Jun. 30, 2024

RELATED PARTY TRANSACTIONS

NOTE 6. RELATED PARTY TRANSACTIONS

The abovementioned payments may be made, at Zander’s discretion, in cash or newly issued common stock of Zander.

The Agreement may be terminated by The Company:

The Agreement may be terminated by either party in the event of a material breach by the other party.

On December 16, 2019 Zander Therapeutics, Inc. (“Zander”), KCL Therapeutics, Inc. (“KCL”) and Regen Biopharma, Inc. (“Regen”) entered into an agreement (“Agreement”) whereby:

2) A $35,000 one time charge due to Zander by Regen (“One Time Charge”) shall be applied pursuant to the Agreement.

3) $75,900 of principal indebtedness due to Regen by Zander and $4,328 of accrued but unpaid interest due by Regen to Zander shall be applied pursuant to the Agreement.

No actions were taken by any of the parties to enforce the terms of the Agreement.

On April 15, 2021 the Agreement was amended as follows so that the material terms and conditions shall be:

a) Zander shall not return the Conversion shares for cancellation and the principal indebtedness of the aforementioned convertible note shall not reflect such return

Zander and Regen are under common control.

As of June 30, 2024, $0 of the principal amount of the Note remains outstanding and all accrued interest has been paid.

On October 8,2021 the Company entered into an agreement with Dr. Brian Koos, MD PhD whereby Dr. Brian Koos would provide services to the Company consisting of :

a) Reviewing existing publications on research being conducted on Checkpoint NR2F6.

b) Identifying the most promising applications for the Company’s technology

c) Drafting a “white paper” on results for 1(b)

d) Making introductions to known experts in appropriate fields identified in 1(b).

BST Partners is controlled by David Koos who serves as the sole officer and director of Regen Biopharma, Inc.

$1,708 lent to the Company by David Koos, the Company’s sole Board Member and Officer, is due and payable at the demand of the holder and bears simple interest at a rate of 15% per annum.

$15,000 lent to the Company by Zander Therapeutics, Inc. is due and payable on May 3. 2025 and bears simple interest at a rate of 10% per annum.

$25,000 lent to the Company by Zander Therapeutics, Inc. is due and payable on June 5. 2025 and bears simple interest at a rate of 10% per annum.

Zander Therapeutics, Inc. and the Company are under common control.

STOCKHOLDERS’ EQUITY

9 Months Ended

Jun. 30, 2024

Equity [Abstract]

STOCKHOLDERS’ EQUITY

NOTE 7. STOCKHOLDERS’ EQUITY

The stockholders’ equity section of the Company contains the following classes of capital stock as of June 30, 2024:

Common stock, $ 0.0001 par value; 5,800,000,000 shares authorized: 4,373,078 shares issued and outstanding.

Series AA Preferred Stock

Series A Preferred Stock

On May 20, 2024 Regen Biopharma, Inc. amended its Certificate of Incorporation adding the following Article 8 which is and reads as follows:

Shares of one class or series of stock may be issued as a share dividend in respect of another class or series.

INVESTMENT SECURITIES, RELATED PARTY

9 Months Ended

Jun. 30, 2024

Investment Securities Related Party

INVESTMENT SECURITIES, RELATED PARTY

NOTE 8. INVESTMENT SECURITIES, RELATED PARTY

On June 11, 2018 Regen Biopharma, Inc. was paid a property dividend consisting of 470,588 of the common shares of Zander Therapeutics, Inc.

Schedule of dividend income
Fair Value of Intellectual Property	$	300,000
Prepaid Expenses		65,661
Due from Employee		0
Note Receivable		40,000
Accrued Interest Receivable		35,000
Investment Securities		258,255
Convertible Note Receivable		10,000
Accounts Payable		30,563
Notes Payable		400,000
Accrued Expenses Related Parties		162,011
Notes Payable Related Party		0
Accrued Expenses		647,072
Enterprise Value		1,948,562
Less: Total Debt		(1,239,646	)
Portion of Enterprise Value Attributable to Shareholders		708,916
Fair Value Per Share	$	0.02

The abovementioned constitute the Company’s sole related party investment securities as of June 30, 2024.

As of June 30, 2024:

	Schedule of comprehensive income
470,588 Common Shares of Zander Therapeutics, Inc.

	Basis		Fair Value		Total Unrealized Gains		Net Unrealized Gain or (Loss) realized during the quarter ended June 30, 2024
$	5,741	$	6,496	$	755	$	(0	)

725,000 Series M Preferred of Zander Therapeutics, Inc.

	Basis		Fair Value		Total Unrealized Loss			Net Unrealized Gain or (Loss) realized during the quarter ended June 30, 2024
$	13,124	$	11,238	$	(1,866	)	$	(0	)

STOCK TRANSACTIONS

9 Months Ended

Jun. 30, 2024

Stock Transactions

STOCK TRANSACTIONS

NOTE 9. STOCK TRANSACTIONS

On April 3, 2024 the Company issued 52,763 common shares for cash consideration of $25,326.

On May 2, 2024 the Company issued 20,068 Series A Preferred shares for nonemployee services .

On May 29, 2024 the Company issued 66,185 common shares for cash consideration of $30,000.

On June 7, 2024 the Company issued 62,207 common shares for cash consideration of $30,000.

On June 20, 2024 the Company issued 75,301 common shares for cash consideration of $50,000.

SUBSEQUENT EVENTS

9 Months Ended

Jun. 30, 2024

Subsequent Events [Abstract]

SUBSEQUENT EVENTS

NOTE 10. SUBSEQUENT EVENTS

On July 3, 2024 9,694,152 Series A Preferred Shares were issued as a dividend to the Shareholders of Record.

On July 12, 2024 the Company sold 135,242 common shares to Coventry pursuant to the terms and conditions of the Equity Line Agreement for total cash consideration of $28,125.

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)

9 Months Ended

Jun. 30, 2024

Accounting Policies [Abstract]

BASIS OF ACCOUNTING

A. BASIS OF ACCOUNTING

PRINCIPLES OF CONSOLIDATION

B. PRINCIPLES OF CONSOLIDATION

Schedule of Derivative liability
Schedule of Derivative liability
Risk Free Interest Rate	5.39	%
Expected Term	(3.53) – (4.16) Yrs
Expected Volatility	1128.35	%
Expected Dividends

INCOME TAXES

H. INCOME TAXES

The Company generated a deferred tax credit through net operating loss carry forward. However, a valuation allowance of 100% has been established.

Interest and penalties on tax deficiencies recognized in accordance with ACS accounting standards are classified as income taxes in accordance with ASC Topic 740-10-50-19.

BASIC EARNINGS (LOSS) PER SHARE

I. BASIC EARNINGS (LOSS) PER SHARE

Basic net loss per share amounts is computed by dividing the net income by the weighted average number of common shares outstanding.

ADVERTISING

J. ADVERTISING

Costs associated with advertising are charged to expense as incurred. Advertising expenses were $0 for the quarters ended June 30, 2023 and June 30, 2024.

NOTES RECEIVABLE

K. NOTES RECEIVABLE

Notes receivable are stated at cost, less impairment, if any.

REVENUE RECOGNITION

L. REVENUE RECOGNITION

INTEREST RECEIVABLE

M. INTEREST RECEIVABLE

Interest receivable is stated at cost, less impairment, if any.

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)

9 Months Ended

Jun. 30, 2024

Accounting Policies [Abstract]

Schedule of Derivative liability

Schedule of Derivative liability
Schedule of Derivative liability
Risk Free Interest Rate	5.39	%
Expected Term	(3.53) – (4.16) Yrs
Expected Volatility	1128.35	%
Expected Dividends

NOTES PAYABLE (Tables)

9 Months Ended

Jun. 30, 2024

Debt Disclosure [Abstract]

Notes payable related party

Notes payable related party
	As of June 30, 2024
David Koos	$	1,708
Zander Therapeutics, Inc.	$	40,000
Total:	$	41,708

Schedule of non related party

Schedule of non related party
Bostonia Partners, Inc	$	48,500
Coventry Enterprises LLC	$	140,000
Total:	$	188,500

INVESTMENT SECURITIES, RELATED PARTY (Tables)

9 Months Ended

Jun. 30, 2024

Investment Securities Related Party

Schedule of dividend income

Schedule of dividend income
Fair Value of Intellectual Property	$	300,000
Prepaid Expenses		65,661
Due from Employee		0
Note Receivable		40,000
Accrued Interest Receivable		35,000
Investment Securities		258,255
Convertible Note Receivable		10,000
Accounts Payable		30,563
Notes Payable		400,000
Accrued Expenses Related Parties		162,011
Notes Payable Related Party		0
Accrued Expenses		647,072
Enterprise Value		1,948,562
Less: Total Debt		(1,239,646	)
Portion of Enterprise Value Attributable to Shareholders		708,916
Fair Value Per Share	$	0.02

Schedule of comprehensive income

	Schedule of comprehensive income
470,588 Common Shares of Zander Therapeutics, Inc.

	Basis		Fair Value		Total Unrealized Gains		Net Unrealized Gain or (Loss) realized during the quarter ended June 30, 2024
$	5,741	$	6,496	$	755	$	(0	)

725,000 Series M Preferred of Zander Therapeutics, Inc.

	Basis		Fair Value		Total Unrealized Loss			Net Unrealized Gain or (Loss) realized during the quarter ended June 30, 2024
$	13,124	$	11,238	$	(1,866	)	$	(0	)

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)	9 Months Ended
	Jun. 30, 2024
Property, Plant and Equipment [Line Items]
Risk Free Interest Rate	5.39%
Expected Volatility	1128.35%
Minimum [Member]
Property, Plant and Equipment [Line Items]
Expected Term	3 years 6 months 10 days
Maximum [Member]
Property, Plant and Equipment [Line Items]
Expected Term	4 years 1 month 28 days

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)	9 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Accounting Policies [Abstract]
Valuation allowance, percent	100.00%
Advertising expense	$ 0	$ 0

GOING CONCERN (Details Narrative) - USD ($)		3 Months Ended			146 Months Ended
GOING CONCERN (Details Narrative) - USD ($)	Sep. 12, 2023	Jun. 30, 2024	Mar. 31, 2024	Dec. 31, 2023	Jun. 30, 2024
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Net loss					$ 20,331,216
Common Stock [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Share price	$ 1.25
Common Stock [Member] \| Coventry Enterprises L L C [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Common shares at per share price	$ 1.50
Resale of stock, shares	10,000
Equity Line Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Purchase value of common stock shares	$ 10,000,000
Par value per share	$ 0.0001
Equity Line Agreement [Member] \| Common Stock [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Issued shares	125,000	258,456	364,057	244,199
Resale of stock, shares	1,126,954
Issued shares, value		$ 135,326	$ 187,937	$ 212,296

NOTES PAYABLE (Details)	Jun. 30, 2024 USD ($)
Related Party [Member]
Short-Term Debt [Line Items]
Notes payable	$ 41,708
David Koos [Member]
Short-Term Debt [Line Items]
Notes payable	1,708
David Koos [Member] \| Related Party [Member]
Short-Term Debt [Line Items]
Notes payable	1,708
Zander Therapeutics Inc [Member] \| Related Party [Member]
Short-Term Debt [Line Items]
Notes payable	$ 40,000

NOTES PAYABLE (Details 1) - Nonrelated Party [Member]	Jun. 30, 2024 USD ($)
Short-Term Debt [Line Items]
Notes payable	$ 188,500
Bostonia [Member]
Short-Term Debt [Line Items]
Notes payable	48,500
Coventry Enterprises L L C [Member]
Short-Term Debt [Line Items]
Notes payable	$ 140,000

NOTES PAYABLE (Details Narrative) - USD ($)		9 Months Ended
NOTES PAYABLE (Details Narrative) - USD ($)	Sep. 12, 2023	Jun. 30, 2024
Unsecured Promissory Note [Member]
Short-Term Debt [Line Items]
Principal amount	$ 175,000
Original issue discount	26,250
Guaranteed interest	26,250
Due and payable in seven equal monthly payments	$ 28,750
Outstanding principal balance		$ 140,000
David Koos [Member]
Short-Term Debt [Line Items]
Due and payable amount		$ 1,708
Interest rate		15.00%
Zander Therapeutics Inc 1 [Member]
Short-Term Debt [Line Items]
Due and payable amount		$ 15,000
Interest rate		10.00%
Zander Therapeutics Inc 2 [Member]
Short-Term Debt [Line Items]
Due and payable amount		$ 25,000
Interest rate		10.00%
Bostonia [Member]
Short-Term Debt [Line Items]
Due and payable amount		$ 48,500
Interest rate		10.00%

CONVERTIBLE NOTES PAYABLE (Details Narrative)	9 Months Ended
CONVERTIBLE NOTES PAYABLE (Details Narrative)	Jun. 30, 2024 USD ($) $ / shares
Convertible Note; March 8, 2016
Short-Term Debt [Line Items]
Issued convertible note in face amount	$ 100,000
Cash issued for convertible note	$ 100,000
Interest in amount of per annum	8.00%
Principal amount	$ 100,000
Convertible Note; April 6, 2016
Short-Term Debt [Line Items]
Issued convertible note in face amount	50,000
Cash issued for convertible note	$ 50,000
Interest in amount of per annum	8.00%
Principal amount	$ 50,000
Convertible Note; October 31, 2016
Short-Term Debt [Line Items]
Issued convertible note in face amount	50,000
Cash issued for convertible note	$ 50,000
Interest in amount of per annum	10.00%
Principal amount	$ 50,000
Convertible Note; May 5, 2017
Short-Term Debt [Line Items]
Issued convertible note in face amount	200,000
Cash issued for convertible note	$ 200,000
Interest in amount of per annum	1000.00%
Principal amount	$ 200,000
Strike price \| $ / shares	$ 75
Derivative liability	$ 800,149
Convertible Note; December 20, 2017
Short-Term Debt [Line Items]
Issued convertible note in face amount	100,000
Cash issued for convertible note	$ 100,000
Interest in amount of per annum	1000.00%
Principal amount	$ 100,000
Derivative liability	400,075
Convertible Note; October 3, 2017
Short-Term Debt [Line Items]
Issued convertible note in face amount	50,000
Cash issued for convertible note	$ 50,000
Interest in amount of per annum	1000.00%
Principal amount	$ 50,000
Derivative liability	$ 200,037

RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)			9 Months Ended
	Jan. 13, 2022	Jun. 23, 2015	Jun. 30, 2024
Related Party Transaction [Line Items]
Non refundable payment descriptions			The Company one-time, non-refundable, upfront payment of one hundred thousand US dollars ($100,000) as a license initiation fee which must be paid within 90 days of June 23, 2015 and an annual non-refundable payment of one hundred thousand US dollars ($100,000) on July 15th, 2016 and each subsequent anniversary of the effective date of the Agreement.
Minimum annual royalties		$ 10,000
Prepaid royalties		$ 10,000
Payments for rent	$ 5,000
David Koos [Member]
Related Party Transaction [Line Items]
Due and payable amount			$ 1,708
Bears simple interest rate			15.00%
Zander Therapeutics
Related Party Transaction [Line Items]
Due and payable amount			$ 15,000
Bears simple interest rate			10.00%
Zander Therapeutics One [Member]
Related Party Transaction [Line Items]
Due and payable amount			$ 25,000
Bears simple interest rate			10.00%
Convertible Note; September 30, 2018
Related Party Transaction [Line Items]
Convertible promissory note			$ 350,000
Cash issued for convertible note			$ 350,000
Interest charge, percent			10.00%
Principal amount			$ 0
David Koos [Member]
Related Party Transaction [Line Items]
Principal amount			1,708
Due and payable amount			$ 710

STOCKHOLDERS’ EQUITY (Details Narrative) - $ / shares	Jun. 30, 2024	Sep. 30, 2023
Class of Stock [Line Items]
Common stock, shares authorized	500,000,000	5,800,000,000
Common stock, shares issued	4,373,078	3,506,366
Common stock, shares outstanding	4,373,078	3,506,366
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	800,000,000	800,000,000
Series AA Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	600,000	600,000
Preferred stock, shares outstanding	34	34
Preferred stock, par value	$ 0.0001
Series A Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares authorized	739,000,000	739,000,000
Preferred stock, shares outstanding	429,619	409,551
Preferred stock, par value	$ 0.0001
Series M Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	60,000,000	60,000,000
Preferred stock, shares outstanding	29,338	29,338
Series NC Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	20,000	20,000
Preferred stock, shares outstanding	15,007	15,007

INVESTMENT SECURITIES, RELATED PARTY (Details) - USD ($)	Jun. 30, 2024	Sep. 30, 2023
Accounts Payable	$ 29,416	$ 29,674
Series M Preferred Stock [Member] \| Zander Therapeutics
Fair Value of Intellectual Property	300,000
Prepaid Expenses	65,661
Due from Employees	0
Note Receivable	40,000
Accrued Investment Income Receivable	35,000
Investment Securities	258,255
Convertible Note Receivable	10,000
Accounts Payable	30,563
Notes Payable	400,000
Accrued Expenses Related Parties	162,011
Notes Payable Related Part	0
Accrued Expenses	647,072
Enterprise Value	1,948,562
Less: Total Debt	(1,239,646)
Portion of Enterprise Value Attributable to Shareholders	$ 708,916
Fair Value per share	$ 0.02

INVESTMENT SECURITIES, RELATED PARTY (Details 1)	9 Months Ended
INVESTMENT SECURITIES, RELATED PARTY (Details 1)	Jun. 30, 2024 USD ($)
Investment securities, total unrealized gains	$ (204,847)
Common Stock [Member] \| Zander Therapeutics
Investment securities, basis	5,741
Investment securities, fair value	6,496
Investment securities, total unrealized gains	755
Investment securities, net unrealized gain or (loss) realized	(0)
Series M Preferred Stock [Member] \| Zander Therapeutics
Investment securities, basis	13,124
Investment securities, fair value	11,238
Investment securities, total unrealized gains	(1,866)
Investment securities, net unrealized gain or (loss) realized	$ (0)

INVESTMENT SECURITIES, RELATED PARTY (Details Narrative) - Zander Therapeutics - USD ($)		1 Months Ended	9 Months Ended
	Jun. 11, 2018	Nov. 29, 2018	Jun. 30, 2024
Number of shares issued for property dividend	470,588		470,588
Series M Preferred Stock [Member]
Number of shares issued in satisfaction of prepaid rent and accrued interest		725,000	725,000
Shares issued in satisfaction of prepaid rent and accrued interest value		$ 13,124

STOCK TRANSACTIONS (Details Narrative) - USD ($)	Jun. 20, 2024	Jun. 07, 2024	May 29, 2024	May 02, 2024	Apr. 03, 2024
Stock Transactions
Issued common shares	75,301	62,207	66,185	20,068	52,763
Cash consideration	$ 50,000	$ 30,000	$ 30,000		$ 25,326

SUBSEQUENT EVENTS (Details Narrative) - Subsequent Event [Member] - USD ($)	Jul. 12, 2024	Jul. 03, 2024
Subsequent Event [Line Items]
Common share issued	135,242
Cash consideration	$ 28,125
Series A Preferred Shares [Member]
Subsequent Event [Line Items]
Shares issued as dividend		9,694,152